Document And Entity Information
Document And Entity Information - shares | 9 Months Ended | |
Sep. 30, 2017 | Nov. 09, 2017 | |
Document Information [Line Items] | ||
Entity Registrant Name | AMYRIS, INC. | |
Entity Central Index Key | 1,365,916 | |
Trading Symbol | amrs | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Smaller Reporting Company | |
Entity Current Reporting Status | Yes | |
Entity Voluntary Filers | No | |
Entity Well-known Seasoned Issuer | No | |
Entity Common Stock, Shares Outstanding (in shares) | 43,033,650 | |
Document Type | 10-Q | |
Document Period End Date | Sep. 30, 2017 | |
Document Fiscal Year Focus | 2,017 | |
Document Fiscal Period Focus | Q3 | |
Amendment Flag | false |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Sep. 30, 2017 | Dec. 31, 2016 |
Assets | ||
Cash and cash equivalents | $ 15,865 | $ 27,150 |
Restricted cash | 4,078 | 4,326 |
Short-term investments | 1,743 | 1,374 |
Accounts receivable, net of allowance of $642 and $501, respectively | 24,922 | 13,977 |
Inventories | 6,410 | 6,213 |
Prepaid expenses and other current assets | 9,244 | 6,083 |
Total current assets | 62,262 | 59,123 |
Property, plant and equipment, net | 50,130 | 53,735 |
Restricted cash, non-current | 958 | 957 |
Recoverable taxes from Brazilian government entities | 17,561 | 13,723 |
Other assets | 7,670 | 2,335 |
Total assets | 138,581 | 129,873 |
Liabilities, Mezzanine Equity and Stockholders' Deficit | ||
Accounts payable | 20,396 | 15,315 |
Deferred revenue | 7,027 | 5,288 |
Accrued and other current liabilities | 28,883 | 30,110 |
Debt, current portion | 6,070 | 25,853 |
Related party debt, current portion | 5,634 | 33,302 |
Total current liabilities | 68,010 | 109,868 |
Long-term debt, net of current portion | 109,205 | 128,744 |
Related party debt, net of current portion | 43,736 | 39,144 |
Derivative liabilities | 89,770 | 6,894 |
Other liabilities | 18,271 | 23,731 |
Total liabilities | 328,992 | 308,381 |
Commitments and contingencies (Note 8) | ||
Stockholders’ deficit: | ||
Preferred stock - $0.0001 par value, 5,000,000 and 5,000,000 shares authorized as of September 30, 2017 and December 31, 2016, respectively, and 56,390 and 0 shares issued and outstanding as of September 30, 2017 and December 31, 2016, respectively | ||
Common stock - $0.0001 par value, 250,000,000 and 500,000,000 shares authorized as of September 30, 2017 and December 31, 2016, respectively; 38,762,112 and 18,273,921 shares issued and outstanding as of September 30, 2017 and December 31, 2016, respectively | 4 | 2 |
Additional paid-in capital - common stock and other | 1,049,299 | 990,895 |
Accumulated other comprehensive loss | (40,601) | (40,904) |
Accumulated deficit | (1,205,050) | (1,134,438) |
Total Amyris, Inc. stockholders’ deficit | (196,348) | (184,445) |
Noncontrolling interest | 937 | 937 |
Total stockholders' deficit | (195,411) | (183,508) |
Total liabilities, mezzanine equity and stockholders' deficit | 138,581 | 129,873 |
Contingently Redeemable Common Stock [Member] | ||
Liabilities, Mezzanine Equity and Stockholders' Deficit | ||
Mezzanine Equity | $ 5,000 | $ 5,000 |
Condensed Consolidated Balance3
Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - USD ($) $ in Thousands | Sep. 30, 2017 | Dec. 31, 2016 |
Allowance for doubtful accounts | $ 642 | $ 501 |
Preferred stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Preferred stock, shares authorized (in shares) | 5,000,000 | 5,000,000 |
Preferred stock, shares issued (in shares) | 56,390 | 0 |
Preferred stock, shares outstanding (in shares) | 56,390 | 0 |
Common stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized (in shares) | 250,000,000 | 500,000,000 |
Common stock, shares issued (in shares) | 38,762,112 | 18,273,921 |
Common stock, shares outstanding (in shares) | 38,762,112 | 18,273,921 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2017 | Sep. 30, 2016 | Sep. 30, 2017 | Sep. 30, 2016 | |
Revenue | ||||
Renewable products | $ 11,315,000 | $ 6,820,000 | $ 32,336,000 | $ 14,883,000 |
Grants and collaborations | 12,882,000 | 19,724,000 | 30,521,000 | 30,071,000 |
Total revenue | 24,197,000 | 26,544,000 | 62,857,000 | 44,954,000 |
Cost and operating expenses | ||||
Cost of products sold | 17,637,000 | 14,876,000 | 47,684,000 | 33,945,000 |
Research and development | 15,185,000 | 12,315,000 | 44,141,000 | 37,397,000 |
Sales, general and administrative | 15,454,000 | 11,381,000 | 44,253,000 | 35,055,000 |
Total cost and operating expenses | 48,276,000 | 38,572,000 | 136,078,000 | 106,397,000 |
Loss from operations | (24,079,000) | (12,028,000) | (73,221,000) | (61,443,000) |
Other income (expense) | ||||
Interest expense | (7,733,000) | (7,927,000) | (29,219,000) | (25,989,000) |
Gain (loss) from change in fair value of derivative instruments | (2,692,000) | (786,000) | 35,422,000 | 41,826,000 |
Gain (loss) upon extinguishment of debt | 461,000 | (217,000) | (3,067,000) | (866,000) |
Other (expense) income, net | (136,000) | 1,402,000 | (576,000) | (1,705,000) |
Total other income (expense) | (10,100,000) | (7,528,000) | 2,560,000 | 13,266,000 |
Loss before income taxes | (34,179,000) | (19,556,000) | (70,661,000) | (48,177,000) |
Benefit from (provision for) income taxes | 318,000 | (148,000) | 49,000 | (402,000) |
Net loss attributable to Amyris, Inc. | (33,861,000) | (19,704,000) | (70,612,000) | (48,579,000) |
Less deemed dividend on capital distribution to related parties | (8,648,000) | |||
Less deemed dividend related to beneficial conversion feature on Series A preferred stock | (562,000) | |||
Less deemed dividend related to beneficial conversion feature on Series B preferred stock | (634,000) | (634,000) | ||
Less deemed dividend related to beneficial conversion feature on Series D preferred stock | (5,757,000) | (5,757,000) | ||
Less cumulative dividends on Series A and Series B preferred stock | (2,567,000) | (4,242,000) | ||
Net loss attributable to Amyris, Inc. common stockholders | $ (42,819,000) | $ (19,704,000) | $ (90,455,000) | $ (48,579,000) |
Net loss per share attributable to common stockholders: | ||||
Basic (in dollars per share) | $ (1.14) | $ (1.19) | $ (3.32) | $ (3.21) |
Diluted (in dollars per share) | $ (1.14) | $ (1.19) | $ (4.61) | $ (4.24) |
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock: | ||||
Basic (in shares) | 37,529,694 | 16,612,690 | 27,280,894 | 15,118,144 |
Diluted (in shares) | 37,529,694 | 16,612,690 | 27,280,894 | 17,891,675 |
Condensed Consolidated Stateme5
Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2017 | Sep. 30, 2016 | Sep. 30, 2017 | Sep. 30, 2016 | |
Comprehensive loss: | ||||
Net loss attributable to Amyris, Inc. common stockholders | $ (42,819) | $ (19,704) | $ (90,455) | $ (48,579) |
Foreign currency translation adjustment, net of tax | 1,402 | (1,884) | 303 | 7,397 |
Comprehensive loss attributable to Amyris, Inc. common stockholders | $ (41,417) | $ (21,588) | $ (90,152) | $ (41,182) |
Condensed Consolidated Stateme6
Condensed Consolidated Statements of Stockholders' Deficit and Mezzanine Equity (Unaudited) - USD ($) $ in Thousands | Series A Preferred Stock [Member]Preferred Stock [Member] | Series A Preferred Stock [Member]Common Stock [Member] | Series A Preferred Stock [Member]Preferred Stock Including Additional Paid in Capital [Member] | Series A Preferred Stock [Member]AOCI Attributable to Parent [Member] | Series A Preferred Stock [Member]Retained Earnings [Member] | Series A Preferred Stock [Member]Noncontrolling Interest [Member] | Series A Preferred Stock [Member]Mezzanine Equity, Common Stock [Member] | Series A Preferred Stock [Member]Mezzanine Equity, Preferred Stock [Member] | Series A Preferred Stock [Member] | Series B Preferred Stock [Member]Preferred Stock [Member] | Series B Preferred Stock [Member]Common Stock [Member] | Series B Preferred Stock [Member]Preferred Stock Including Additional Paid in Capital [Member] | Series B Preferred Stock [Member]AOCI Attributable to Parent [Member] | Series B Preferred Stock [Member]Retained Earnings [Member] | Series B Preferred Stock [Member]Noncontrolling Interest [Member] | Series B Preferred Stock [Member]Mezzanine Equity, Common Stock [Member] | Series B Preferred Stock [Member]Mezzanine Equity, Preferred Stock [Member] | Series B Preferred Stock [Member] | Series D Preferred Stock [Member]Preferred Stock [Member] | Series D Preferred Stock [Member]Common Stock [Member] | Series D Preferred Stock [Member]Preferred Stock Including Additional Paid in Capital [Member] | Series D Preferred Stock [Member]AOCI Attributable to Parent [Member] | Series D Preferred Stock [Member]Retained Earnings [Member] | Series D Preferred Stock [Member]Noncontrolling Interest [Member] | Series D Preferred Stock [Member]Mezzanine Equity, Common Stock [Member] | Series D Preferred Stock [Member]Mezzanine Equity, Preferred Stock [Member] | Series D Preferred Stock [Member] | Deemed Dividend on Capital Distribution to Related Parties [Member]Preferred Stock [Member] | Deemed Dividend on Capital Distribution to Related Parties [Member]Common Stock [Member] | Deemed Dividend on Capital Distribution to Related Parties [Member]Preferred Stock Including Additional Paid in Capital [Member] | Deemed Dividend on Capital Distribution to Related Parties [Member]AOCI Attributable to Parent [Member] | Deemed Dividend on Capital Distribution to Related Parties [Member]Retained Earnings [Member] | Deemed Dividend on Capital Distribution to Related Parties [Member]Noncontrolling Interest [Member] | Deemed Dividend on Capital Distribution to Related Parties [Member]Mezzanine Equity, Common Stock [Member] | Deemed Dividend on Capital Distribution to Related Parties [Member]Mezzanine Equity, Preferred Stock [Member] | Deemed Dividend on Capital Distribution to Related Parties [Member] | Preferred Stock [Member] | Common Stock [Member] | Preferred Stock Including Additional Paid in Capital [Member] | AOCI Attributable to Parent [Member] | Retained Earnings [Member] | Noncontrolling Interest [Member] | Mezzanine Equity, Common Stock [Member] | Mezzanine Equity, Preferred Stock [Member] | Total |
Balance (in shares) at Dec. 31, 2015 | 13,742,019 | ||||||||||||||||||||||||||||||||||||||||||||
Balance at Dec. 31, 2015 | $ 2 | $ 926,235 | $ (47,198) | $ (1,037,104) | $ (391) | $ (158,456) | |||||||||||||||||||||||||||||||||||||||
Issuance of common stock upon conversion of debt (in shares) | 695,388 | ||||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock upon conversion of debt | 9,472 | 9,472 | |||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock for settlement of debt principal payments (in shares) | 2,062,357 | ||||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock for settlement of debt principal payments | 13,509 | 13,509 | |||||||||||||||||||||||||||||||||||||||||||
Issuance of contingently redeemable common stock (in shares) | 292,398 | ||||||||||||||||||||||||||||||||||||||||||||
Issuance of contingently redeemable common stock | 5,000 | ||||||||||||||||||||||||||||||||||||||||||||
Issuance of warrants with debt private placement and collaboration agreements | 4,387 | 4,387 | |||||||||||||||||||||||||||||||||||||||||||
Contribution upon restructuring of Fuels JV | 4,252 | 4,252 | |||||||||||||||||||||||||||||||||||||||||||
Acquisition of noncontrolling interest | (323) | 277 | (46) | ||||||||||||||||||||||||||||||||||||||||||
Shares issued from restricted stock settlement (in shares) | 83,672 | ||||||||||||||||||||||||||||||||||||||||||||
Shares issued from restricted stock settlement | (202) | (202) | |||||||||||||||||||||||||||||||||||||||||||
Shares issued upon ESPP purchase (in shares) | 15,122 | ||||||||||||||||||||||||||||||||||||||||||||
Shares issued upon ESPP purchase | 123 | 123 | |||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock upon exercise of stock options, net of restricted stock (in shares) | 9 | ||||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock upon exercise of stock options, net of restricted stock | |||||||||||||||||||||||||||||||||||||||||||||
Stock-based compensation | 5,645 | 5,645 | |||||||||||||||||||||||||||||||||||||||||||
Foreign currency translation adjustment | 7,397 | 7,397 | |||||||||||||||||||||||||||||||||||||||||||
Net loss | (48,579) | (48,579) | |||||||||||||||||||||||||||||||||||||||||||
Balance (in shares) at Sep. 30, 2016 | 16,890,965 | ||||||||||||||||||||||||||||||||||||||||||||
Balance at Sep. 30, 2016 | $ 2 | 963,098 | (39,801) | (1,085,683) | (114) | 5,000 | (162,498) | ||||||||||||||||||||||||||||||||||||||
Balance (in shares) at Dec. 31, 2016 | 18,273,921 | ||||||||||||||||||||||||||||||||||||||||||||
Balance at Dec. 31, 2016 | $ 2 | 990,895 | (40,904) | (1,134,438) | 937 | 5,000 | (183,508) | ||||||||||||||||||||||||||||||||||||||
Issuance of common stock upon conversion of debt (in shares) | 2,257,786 | ||||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock upon conversion of debt | 14,153 | 14,153 | |||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock for settlement of debt principal payments (in shares) | 1,246,165 | ||||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock for settlement of debt principal payments | 10,708 | 10,708 | |||||||||||||||||||||||||||||||||||||||||||
Shares issued from restricted stock settlement (in shares) | 134,479 | ||||||||||||||||||||||||||||||||||||||||||||
Shares issued from restricted stock settlement | (391) | (391) | |||||||||||||||||||||||||||||||||||||||||||
Shares issued upon ESPP purchase (in shares) | 16,759 | ||||||||||||||||||||||||||||||||||||||||||||
Shares issued upon ESPP purchase | 69 | $ 69 | |||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock upon exercise of stock options, net of restricted stock (in shares) | 133 | ||||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock upon exercise of stock options, net of restricted stock | |||||||||||||||||||||||||||||||||||||||||||||
Stock-based compensation | 3,942 | 3,942 | |||||||||||||||||||||||||||||||||||||||||||
Foreign currency translation adjustment | 303 | 303 | |||||||||||||||||||||||||||||||||||||||||||
Net loss | (70,612) | (70,612) | |||||||||||||||||||||||||||||||||||||||||||
Issuance of preferred stock for cash (in shares) | 22,140 | 55,700 | 12,958 | ||||||||||||||||||||||||||||||||||||||||||
Issuance of preferred stock for cash | $ 5,476 | $ 1,300 | $ 5,476 | $ 6,197 | $ 6,197 | ||||||||||||||||||||||||||||||||||||||||
Issuance of Series B preferred stock upon conversion of debt, net of issuance costs of $0 (in shares) | 40,204 | ||||||||||||||||||||||||||||||||||||||||||||
Issuance of Series B preferred stock upon conversion of debt, net of issuance costs of $0 | 11,530 | ||||||||||||||||||||||||||||||||||||||||||||
Issuance of shares due to rounding from reverse stock split (in shares) | 6,473 | ||||||||||||||||||||||||||||||||||||||||||||
Issuance of shares due to rounding from reverse stock split | |||||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock for cash (in shares) | 2,826,711 | ||||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock for cash | 5,527 | 5,527 | |||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock upon conversion of preferred stock (in shares) | (74,612) | 11,842,669 | |||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock upon conversion of preferred stock | $ 2 | 2 | |||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock for settlement of debt interest payments (in shares) | 400,967 | ||||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock for settlement of debt interest payments | 3,436 | 3,436 | |||||||||||||||||||||||||||||||||||||||||||
Beneficial conversion feature of Series A preferred stock | 562 | 562 | 634 | 634 | 5,757 | 5,757 | |||||||||||||||||||||||||||||||||||||||
Deemed dividend | $ (562) | $ (562) | $ (634) | $ (634) | $ (5,757) | $ (5,757) | $ (8,648) | $ (8,648) | |||||||||||||||||||||||||||||||||||||
Reclassification from mezzanine equity to permanent equity | 12,830 | (12,830) | $ 12,830 | ||||||||||||||||||||||||||||||||||||||||||
Shares issued upon exercise of warrants (in shares) | 1,756,048 | 1,722,042 | |||||||||||||||||||||||||||||||||||||||||||
Shares issued upon exercise of warrants | 5,105 | $ 5,105 | |||||||||||||||||||||||||||||||||||||||||||
Balance (in shares) at Sep. 30, 2017 | 56,390 | 38,762,112 | |||||||||||||||||||||||||||||||||||||||||||
Balance at Sep. 30, 2017 | $ 4 | $ 1,049,299 | $ (40,601) | $ (1,205,050) | $ 937 | $ 5,000 | $ (195,411) |
Condensed Consolidated Stateme7
Condensed Consolidated Statements of Stockholders' Deficit and Mezzanine Equity (Unaudited) (Parentheticals) $ in Thousands | 9 Months Ended |
Sep. 30, 2017USD ($) | |
Series A Preferred Stock [Member] | |
Issuance costs | $ 562 |
Series B Preferred Stock [Member] | |
Issuance costs | 860 |
Issuance costs | 0 |
Series D Preferred Stock [Member] | |
Issuance costs | $ 176 |
Condensed Consolidated Stateme8
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 9 Months Ended | |
Sep. 30, 2017 | Sep. 30, 2016 | |
Operating activities | ||
Net loss | $ (70,612,000) | $ (48,579,000) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation and amortization | 8,124,000 | 8,561,000 |
Loss (gain) on disposal of property, plant and equipment | 37,000 | (136,000) |
Stock-based compensation | 3,942,000 | 5,645,000 |
Accretion of debt discount and issuance costs | 10,108,000 | 9,190,000 |
Loss upon extinguishment of debt | 3,067,000 | 866,000 |
Receipt of equity in connection with collaboration arrangements revenue | (2,660,000) | |
Provision for doubtful accounts | 141,000 | |
Gain from change in fair value of derivative instruments | (35,054,000) | (41,826,000) |
Loss on foreign currency exchange rates | (205,000) | 1,662,000 |
Changes in assets and liabilities: | ||
Accounts receivable | (11,088,000) | (1,357,000) |
Inventories | (126,000) | 3,868,000 |
Recoverable taxes from Brazilian government entities | (3,838,000) | (3,069,000) |
Prepaid expenses and other assets | (9,124,000) | 1,735,000 |
Accounts payable | 3,119,000 | 4,306,000 |
Accrued and other liabilities | 404,000 | 13,408,000 |
Deferred revenue | 1,113,000 | 343,000 |
Net cash used in operating activities | (102,652,000) | (45,383,000) |
Investing activities | ||
Purchase of short-term investments | (3,618,000) | (3,073,000) |
Maturities of short-term investments | 5,799,000 | 3,296,000 |
Sale of short-term investments | 43,000 | |
Purchases of property, plant and equipment | (487,000) | (719,000) |
Net cash provided by (used in) investing activities | 1,737,000 | (496,000) |
Financing activities | ||
Proceeds from debt issued, net of discounts and issuance costs | 13,965,000 | 13,275,000 |
Proceeds from debt issued to related parties | 25,000,000 | |
Proceeds from issuance of contingently redeemable common stock | 5,000,000 | |
Proceeds from exercises of common stock options, net of repurchase | 147,000 | 123,000 |
Principal payments on debt | (26,708,000) | (7,442,000) |
Principal payments on capital leases | (977,000) | |
Change in restricted cash related to contingently redeemable common stock | 1,022,000 | |
Employees' taxes paid upon vesting of restricted stock units | (87,000) | (202,000) |
Net cash provided by financing activities | 89,766,000 | 34,777,000 |
Effect of exchange rate changes on cash and cash equivalents | (136,000) | (308,000) |
Net decrease in cash and cash equivalents | (11,285,000) | (11,410,000) |
Cash and cash equivalents at beginning of period | 27,150,000 | 11,992,000 |
Cash and cash equivalents at end of period | 15,865,000 | 582,000 |
Supplemental disclosures of cash flow information: | ||
Cash paid for interest | 6,805,000 | 4,679,000 |
Supplemental disclosures of non-cash investing and financing activities: | ||
Acquisition of property, plant and equipment under accounts payable, accrued liabilities and notes payable | (1,045,000) | (1,485,000) |
Financing of equipment | 953,000 | 1,276,000 |
Financing of insurance premium under notes payable | (191,000) | (315,000) |
Issuance of common stock for settlement of debt principal and interest payments | 14,144,000 | 13,506,000 |
Issuance of convertible preferred stock upon conversion of debt | 40,204,000 | |
Issuance of common stock upon conversion of debt | 28,702,000 | 9,471,000 |
Accrued interest added to debt principal | 1,745,000 | 2,052,000 |
Non-cash investment in joint venture | 600,000 | |
Cancellation of debt and accrued interest on disposal of interest in affiliate | 4,252,000 | |
May 2017 Offerings [Member] | ||
Financing activities | ||
Proceeds from sale of convertible preferred stock in May 2017 Offerings, net of issuance costs | 50,661,000 | |
August 2017, Vivo Offering [Member] | ||
Financing activities | ||
Proceeds from sale of convertible preferred stock in May 2017 Offerings, net of issuance costs | 24,824,000 | |
August 2017 DSM Offering [Member] | ||
Financing activities | ||
Proceeds from sale of convertible preferred stock in May 2017 Offerings, net of issuance costs | $ 25,942,000 |
Note 1 - The Company
Note 1 - The Company | 9 Months Ended |
Sep. 30, 2017 | |
Notes to Financial Statements | |
Nature of Operations [Text Block] | 1. Amyris, Inc. (the Company or Amyris) is a leading industrial biotechnology company that is applying its technology platform to engineer, manufacture and sell high performance products into the Health and Nutrition, Personal Care and Performance Materials markets. The Company's proven technology platform enables the Company to rapidly engineer microbes and use them as catalysts to metabolize renewable, plant-sourced sugars into large volume, high-value ingredients. The Company's biotechnology platform and industrial fermentation process replace existing complex and expensive chemical manufacturing processes. The Company has successfully used its technology to develop and produce at commercial volumes five The Company believes that industrial synthetic biology represents a third three Liquidity The Company has incurred significant operating losses since its inception and expects to continue to incur losses and negative cash flows from operations through at least the first 2018. September 30, 2017, $5.7 $50.7 December 31, 2016 $1.2 $17.6 $28.5 December 31, 2016 As of September 30, 2017, $23.7 $164.6 $11.7 December 31, 2018 $74.5 $20.4 These factors raise substantial doubt about the Company’s ability to continue as a going concern within one not 12 2017 2018 may may During the nine September 30, 2017, • In January, February May 2017, $21.0 November 2017 April 2019; • In May 2017, 17.38% $0.0001 17.38% $0.0001 $50.7 • In April May 2017, $35.8 • In May 2017, $29.0 • In May 2017, $21.8 $86.6 • In August 2017, $0.0001 $24.8 • In August 2017, $25.9 See Note 5, 7, The Company expects to fund operations for the foreseeable future with cash and investments currently on hand, cash inflows from collaborations, grants, product sales and equity and debt financings, to the extent necessary. Some of our research and development collaborations are subject to risk that we may not may not 2017 2018 |
Note 2 - Summary of Significant
Note 2 - Summary of Significant Accounting Policies | 9 Months Ended |
Sep. 30, 2017 | |
Notes to Financial Statements | |
Significant Accounting Policies [Text Block] | 2. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (GAAP) and applicable rules and regulations of the Securities and Exchange Commission regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. As such, the information included in this quarterly report on Form 10 10 December 31, 2016. The condensed consolidated balance sheet as of December 31, 2016 not not December 31, 2017. There have been no 10 December 31, 2016 The accompanying interim condensed consolidated financial statements and related disclosures are unaudited, have been prepared on the same basis as the annual consolidated financial statements, and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the results of operations for the periods presented. In the nine September 30, 2017 • ASU 2015 11, Inventory (Topic 330 • ASU 2016 06, Derivatives and Hedging (Topic 815 • ASU 2016 09, Compensation—Stock Compensation (Topic 718 None Use of Estimates The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the periods reported. Actual results could differ from these estimates, and such differences may Reverse Stock Split On June 5, 2017, 1 15 $0.0001 500,000,000 250,000,000. first first may The par value, number of shares outstanding and number of authorized shares of preferred stock were not |
Note 3 - Fair Value Measurement
Note 3 - Fair Value Measurement | 9 Months Ended |
Sep. 30, 2017 | |
Notes to Financial Statements | |
Financial Instruments Disclosure [Text Block] | 3. For information about our fair value policies, and methods and assumptions used in estimating the fair value of our financial assets and liabilities, see Note 2, 3, 8 10 December 31, 2016. Assets and Liabilities Measured and Recorded at Fair Value on a Recurring Basis The following tables summarize, for assets or liabilities measured at fair value, the respective fair value and the classification by level of input within the fair value hierarchy (in thousands): September 30, 2017 December 31, 2016 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets Money market funds $ 12,000 $ — $ — $ 12,000 $ 1,549 $ — $ — $ 1,549 Certificates of deposit 1,943 — — 1,943 1,373 — — 1,373 Total assets measured and recorded at fair value $ 13,943 $ — $ — $ 13,943 $ 2,922 $ — $ — $ 2,922 Liabilities Embedded derivatives in connection with the issuance of debt and equity instruments $ — $ — $ 21,069 $ 21,069 $ — $ — $ 4,135 $ 4,135 Freestanding derivative instruments in connection with the issuance of equity instruments — — 66,673 66,673 — — — — Currency interest rate swap derivative liability — 2,552 — 2,552 — 3,343 — 3,343 Total liabilities measured and recorded at fair value $ — $ 2,552 $ 87,742 $ 90,294 $ — $ 3,343 $ 4,135 $ 7,478 There were no Derivative Liabilities Recognized in Connection with the Issuance of Debt and Equity Instruments The following table provides a reconciliation of the beginning and ending balances for the Company's derivative liabilities recognized in connection with the issuance of debt and equity instruments, measured at fair value using significant unobservable inputs (Level 3 2017 2016 Balance at January 1 $ 4,136 $ 46,430 Gain from change in fair value of derivative liabilities (14,190 ) — Additions 129,492 (2,734 ) Derecognition upon conversion or extinguishment (31,696 ) (39,869 ) Balance at September 30 $ 87,742 $ 3,827 The derivative liabilities recognized in connection with the issuance of debt and equity instruments represent the fair value of the make-whole provisions of the Series A and B Preferred Stock as well as the cash and anti-dilution warrants issued concurrently with the Series A, B and D Preferred Stock (see Note 7, 2014 144A 2015 144A 5, September 30, 2017 December 31, 2016, $87.7 $4.1 The market-based assumptions and estimates used in applying a Monte Carlo simulation approach and Black-Scholes-Merton option value approach for valuing the derivative liabilities in connection with debt and equity instruments include amounts in the following ranges and amounts: September 30, 2017 December 31, 2016 Risk-free interest rate 1.32% - 2.33% 0.55% - 1.31% Risk-adjusted yields 19.40% - 29.53% 12.80% - 22.93% Stock price volatility 45% - 80% 45% Probability of change in control 5% 5% Stock price $3.20 $3.93 $10.95 Credit spread 18.04% - 28.13% 11.59% - 21.64% Estimated conversion dates 2017 - 2022 2017 - 2019 The valuation of the embedded derivatives in connection with the issuance of debt and equity instruments and freestanding derivative instruments in connection with the issuance of equity instruments can be significantly affected by changes in valuation assumptions. For example, all other things being equal, a decrease/increase in the Company’s stock price, probability of change of control, credit spread, term to maturity/conversion or stock price volatility decreases/increases the valuation of the liabilities, whereas a decrease/increase in risk adjusted yields or risk-free interest rates increases/decreases the valuation of the liabilities. Certain of the Company’s debt instruments outstanding in the form of convertible notes also include conversion price adjustment features whereby, for example, issuances of equity or equity-linked securities by the Company at prices lower than the conversion price then in effect for such notes result in a reset or adjustment of the conversion price of such notes, which increases the value of the embedded derivative liabilities. A third 5, Currency Interest Rate Swap Derivative Liability In June 2012, 5, R$22.0 US$6.9 September 30, 2017 3.94%. Changes in Fair Value Changes in the fair value of assets or liabilities measured at fair value on a recurring basis are recognized in “Gain (loss) from change in fair value of derivative instruments" in the condensed consolidated statements of operations as follows (in thousands): Three Months Ended Nine Months Ended Type of derivative contract 2017 2016 2017 2016 Embedded derivatives and freestanding financial instruments in connection with the issuance of debt and equity $ (3,107 ) $ (624 ) $ 34,911 $ 39,869 Currency interest rate swaps 415 (162 ) 511 1,957 Total gain (loss) from change in fair value of derivative instruments $ (2,692 ) $ (786 ) $ 35,422 $ 41,826 Assets and Liabilities Recorded at Carrying Value Financial Assets and Liabilities The carrying amounts of certain financial instruments, such as cash equivalents, accounts receivable, accounts payable and accrued liabilities, approximate fair value due to their relatively short maturities and low market interest rates, if applicable. Loans payable, credit facilities and convertible notes are recorded at carrying value, which is representative of fair value at the date of acquisition. The Company estimates the fair value of loans payable and credit facilities using observable market-based inputs (Level 2 3 September 30, 2017 $17.2 $49.4 $98.1 September 30, 2017 $12.2 $25.2 $108.0 $7.1 September 30, 2017. Cost-method Investment In April 2017, 850,115 December 2016. $3.2 40%. |
Note 4 - Balance Sheet Componen
Note 4 - Balance Sheet Components | 9 Months Ended |
Sep. 30, 2017 | |
Notes to Financial Statements | |
Supplemental Balance Sheet Disclosures [Text Block] | 4. Accounts Receivable, Net Accounts receivable, net is comprised of the following (in thousands): September 30, December 31, Accounts receivable $ 15,462 $ 13,583 Related party accounts receivable 10,102 895 25,564 14,478 Less: allowance for doubtful accounts (642 ) (501 ) Accounts receivable, net $ 24,922 $ 13,977 Inventories Inventories are stated at the lower of cost or net realizable value and are comprised of the following (in thousands): September 30, December 31, Raw materials $ 3,236 $ 3,159 Work-in-process 885 1,848 Finished goods 2,289 1,206 Inventories $ 6,410 $ 6,213 Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets is comprised of the following (in thousands): September 30, 2017 December 31, 2016 Prepayments, advances and deposits $ 7,149 $ 3,727 Prepaid insurance 970 645 Other 1,125 1,711 Prepaid expenses and other current assets $ 9,244 $ 6,083 Property, Plant and Equipment, net Property, plant and equipment, net is comprised of the following (in thousands): September 30, 2017 December 31, 2016 Machinery and equipment $ 88,532 $ 82,688 Leasehold improvements 39,150 38,785 Computers and software 9,898 9,585 Buildings 4,834 4,699 Construction in progress 259 2,216 Furniture and office equipment, vehicles and land 2,985 2,957 145,658 140,930 Less: accumulated depreciation and amortization (95,528 ) (87,195 ) Property, plant and equipment, net $ 50,130 $ 53,735 Property, plant and equipment, net includes $3.9 $3.1 September 30, 2017 December 31, 2016, $1.4 $1.0 September 30, 2017 December 31, 2016, Depreciation and amortization expense, including amortization of assets under capital leases was $2.7 $2.9 three September 30, 2017 2016, $8.1 $8.6 nine September 30, 2017 2016, Other Assets Other assets is comprised of the following (in thousands): September 30, 2017 December 31, 2016 Cost-method investment in SweeGen $ 3,233 $ — Deposits 2,516 409 Goodwill 560 560 Other 1,361 1,366 Other assets $ 7,670 $ 2,335 Accrued and Other Current Liabilities Accrued and other current liabilities are comprised of the following (in thousands): September 30, December 31, Payroll and related expenses $ 6,549 $ 6,344 Accrued interest 5,586 4,847 SMA relocation accrual 4,554 3,641 Tax-related liabilities 3,575 2,610 Professional services 3,491 6,876 Other 5,128 5,792 Total accrued and other current liabilities $ 28,883 $ 30,110 Other Liabilities Other non-current liabilities are comprised of the following (in thousands): September 30, December 31, Deferred rent, net of current portion $ 8,139 $ 8,906 Deferred revenue, net of current portion 3,744 6,650 Accrued interest, net of current portion 3,642 5,542 Capital lease obligation, net of current portion 111 334 Other liabilities 2,635 2,299 Total other liabilities $ 18,271 $ 23,731 |
Note 5 - Long-term Debt
Note 5 - Long-term Debt | 9 Months Ended |
Sep. 30, 2017 | |
Notes to Financial Statements | |
Debt Disclosure [Text Block] | 5. Net carrying amounts of debt are as follows (in thousands): September 30, 2017 December 31, 2016 Convertible notes 2015 Rule 144A convertible notes $ 31,108 $ 22,766 2014 Rule 144A convertible notes 18,544 22,010 August 2013 financing convertible notes 1,042 9,247 Fidelity notes — 14,983 December 2016 and June 2017 amended notes — 9,975 50,694 78,981 Related party convertible notes August 2013 financing convertible notes 22,290 21,814 2014 Rule 144A convertible notes 21,417 17,320 R&D note 3,663 3,620 47,370 42,754 Loans payable Senior secured loan facility 28,156 27,658 Guanfu credit facility 20,446 19,564 Nossa Caixa and Banco Pine notes 9,917 11,136 Other loans payable 5,283 15,391 Other credit facilities 779 1,868 64,581 75,617 Related party loans payable February 2016 related party private placement 2,000 18,691 Other related party loans payable — 11,000 2,000 29,691 Total debt 164,645 227,043 Less: current portion (11,704 ) (59,155 ) Long-term debt, net of current portion $ 152,941 $ 167,888 Convertible Notes 2015 144A In October 2015, $57.6 9.50% 2019 2015 144A $54.4 2015 144A 9.50% April 15 October 15 2015 144A 92.5% April 15, 2016 2017 October 15, 2016 October 15, 2017 2015 144A April 15, 2019 The 2015 144A 58.2076 $1,000 2015 144A September 30, 2017 ( $17.18 2015 144A April 15, 2019, 0.75%. may 92.5% September 30, 2017, In January 2017, $19.1 2015 144A 2015 144A $15.3 2015 144A 2015 144A 3,652,935 2015 144A 2014 144A In May 2014, $75.0 6.50% 2019 2014 144A 2014 144A $72.0 $9.7 2014 144A $24.7 2014 144A October 2015, $57.6 2015 144A $18.3 $22.9 2014 144A 2014 144A 6.5%, May 15 November 15 2014 144A May 15, 2019, The 2014 144A 17.8073 $1,000 2014 144A September 30, 2017 ( $56.16 5, 2014 144A August 2013 In August 2013, August 2013 $73.0 August 2013 August 2013 August 2013 two October 2013, August 2013 first August 2013 $7.6 first October 2013, first August 2013 $51.8 $7.6 $44.2 $35.0 $9.2 $35.0 $9.2 $19.9 sixty October 16, 2018). 5% six September 30, 2017, may six In December 2013, August 2013 $3.0 second August 2013 January 2014, $34.0 second August 2013 $25.0 $3.0 $6.0 $6.0 $9.4 sixty January 15, 2019). 10% September 30, 2017, The conversion price of the Tranche Notes is $5.2977 September 30, 2017 Fidelity Notes In 2012, $25.0 March 1, 2017 3.0% $106.02 October 2015, $57.6 $8.8 $9.7 January 2017, $19.1 2015 144A $15.3 1:1.25 $1.00 $1.25 2015 144A not $0.1 nine September 30, 2017. December 2016 June 2017 In December 2016, December 2016 $10.0 December 2016 $9.9 December 2016 May 2017. In April 2017, April 2017 $15.0 April 2017 April 2017, April 2017 $7.0 $6.9 May 2017. In May 2017, April 2017 December 2016 April 2017 December 2016 April 2017 may 20% 70% On June 30, 2017, April 2017 $3.0 $3.0 August 2017. Unless earlier converted or redeemed, the Amended Notes will mature on or about the 18 118% not 50% $200,000. 118% $28.50 September 30, 2017 ( 4.99% not 9.99%, not 61 3,645,118 may not As of September 30, 2017, no $5.0 April 2017 Related Party Convertible Notes August 2013 As of September 30, 2017 December 31, 2016, $21.2 $19.8 $1.1 $2.0 2014 144A As of September 30, 2017 December 31, 2016, $24.7 $24.7 2014 144A $3.3 $7.4 R&D Note In March 2016, $3.7 $105.0 2012. February 2017, March 1, 2017 May 15, 2017. May 2017, May 15, 2017 March 31, 2018, ( 1.5% 12.0%, May 16, 2017, December 31, 2017 $46.20 September 30, 2017 ( 10 Loans Payable Senior Secured Loan Facility In March 2014, $25.0 June 2014, March 2015 November 2015 $31.0 $16.0 $1.5 In June 2016, 50% October 2016, fourth $1 On January 11, 2017, October 15, 2018 No January 2017, fifth $3 15, not June 2016, September 30, 2017 Certain of the loans under the Senior Secured Loan Facility bear interest at a rate per annum equal to the greater of (i) the prime rate reported in the Wall Street Journal plus 6.25% 9.50%, 5.25% 8.5%, may 101% $3.3 $425,000 December 31, 2017 $450,000 December 2016. Guanfu Credit Facility In October 2016, $25.0 December 31, 2016, $25.0 five 10% March 31, 2017. may Upon the occurrence of certain specified events of default under the Guanfu Credit Facility, the Company will grant to Guanfu an exclusive, royalty-free, global license to certain intellectual property useful in connection with Guanfu’s existing commercial relationship with the Company. In addition, in the event the Company fails to pay interest or principal under the Guanfu Note within ten 90% Nossa Caixa and Banco Pine Notes: July 2012, July 2012 July 2012 R$52.0 US$16.4 September 30, 2017 R$68.0 US$21.5 September 30, 2017 July 2012 R$52.0 US$16.4 September 30, 2017 July 15, 2022 5.5% 30 August 15, 2014, 15, Other Loans Payable Salisbury Note: December 2016, $3.5 5% 13 January 1, 2017 January 2017, Nikko Note: December 2016, 9, $3.9 5% 13 January 1, 2017 ( 5% 5 first 10% $400,000 $100,000 January 1, 2017, February 1, 2017, March 1, 2017 April 1, 2017 fourth may Aprinnova Working Capital Loans: February 2017, $1.5 $375,000 May 1, 2017, August 1, 2017, November 1, 2017 February 1, 2018. August 2017, second $1.5 July 31, 2018, 2.75% Ginkgo Notes: October 2016, $8.5 April 2017, $3.0 13.50% May 15, 2017. Related Party Loans Payable February 2016 In February 2016, $20.0 February 2016 190,477 $0.15 September 30, 2017 February 2016 $20.0 $16.0 February 2016 152,381 $2.0 February 2016 19,048 $2.0 February 2016 19,048 The February 2016 13.50% May 15, 2017. May 2017, February 2016 7, May 2017, February 2016 November 15, 2017. 15, The February 2016 five September 30, 2017, February 2016 none February 2016 Other Related Party Loans Payable In June October 2016, $11.0 13.50% May 15, 2017. May 2017, 7, Maturity Treatment Agreement In July 2015, 2015 $71.0 $70.0 $34.50 2015 2015 July 29, 2015, 2014 144A not 2015 not May 2017, 2014 144A $9.7 $10.0 no September 30, 2017, not $21.2 $21.2 See Note 15, September 30, 2017. Future Minimum Payments Future minimum payments under the Company's debt agreements as of September 30, 2017 Years ending December 31: Convertible Related Loans Related Credit Total 2017 (remaining three months) $ 2,690 $ 803 $ 1,096 $ 2,487 $ 1,772 $ 8,848 2018 5,160 20,938 5,787 — 33,771 65,656 2019 69,339 35,298 2,766 — 2,580 109,983 2020 — — 2,656 — 2,500 5,156 2021 — — 2,544 — 27,396 29,940 Thereafter — — 4,115 — — 4,115 Total future minimum payments 77,189 57,039 18,964 2,487 68,019 223,698 Less: amount representing interest (1) (26,495 ) (9,669 ) (3,764 ) (487 ) (18,638 ) (59,053 ) Present value of minimum debt payments 50,694 47,370 15,200 2,000 49,381 164,645 Less: current portion — (3,700 ) (5,492 ) (2,000 ) (512 ) (11,704 ) Noncurrent portion of debt $ 50,694 $ 43,670 $ 9,708 $ — $ 48,869 $ 152,941 ( 1 |
Note 6 - Mezzanine Equity
Note 6 - Mezzanine Equity | 9 Months Ended |
Sep. 30, 2017 | |
Notes to Financial Statements | |
Mezzanine Equity Disclosure [Text Block] | 6. Mezzanine equity is comprised of the following (in thousands): September 30, December 31, Contingently redeemable common stock $ 5,000 $ 5,000 Common Stock In May 2016, 292,398 $17.10 $5.0 not $5.0 2017. $5.0 third 10%. September 30, 2017, $5.0 not |
Note 7 - Stockholders' Deficit
Note 7 - Stockholders' Deficit | 9 Months Ended |
Sep. 30, 2017 | |
Notes to Financial Statements | |
Stockholders' Equity Note Disclosure [Text Block] | 7. August 2017 On August 7, 2017, in a private placement (the August 2017 • 25,000 August 2017 $1,000 • a warrant to purchase 3,968,116 $6.30 five August 2017 • the August 2017 Net proceeds to the Company were $25.9 The exercise price of the August 2017 three August 7, 2017 ( August 2017 The August 2017 $6.30, $0.10 August 2017 five The effectiveness of the anti-dilution adjustment provision of the August 2017 August 2017 August 2017 September 30, 2017, August 2017 not August 2017 not In connection with the August 2017 not October 31, 2017, ( May 11, 2018 In connection with the August 2017 May 11, 2017 ( one 4.5%, not May 2017 May 2018 three no not, 33% one 1933, May 2017 second 10%, August 2017 In addition, pursuant to the Amended and Restated DSM Stockholder Agreement, the Company and DSM agreed to negotiate in good faith regarding an agreement concerning the development of certain products in the Health and Nutrition field and, in the event that the parties did not 90 August 2017 August 2017 first August 2017 $5 not $25 September 2017, August 2017 In connection with the August 2017 $25.9 $9.0 October 28, 2017, 2018. $7.1 605 50, $34.0 August 2017 August 2017 August 2017 3 August 2017 $5.5 $0.2 $9.9 August 2017 August 2017 $10.6 August 2017 August 2017 September 30, 2017 The DSM Credit Letter is reported as deferred revenue and its fair value has been determined based on the assumptions that DSM will realize its credit over the next 18 4 50% 90% 8.6% $34.0 $0.7 three nine September 30, 2017. 10, August 2017 On August 3, 2017, August 2017 • 2,826,711 $4.26 • 12,958 $1,000 • warrants to purchase an aggregate of 5,575,118 $6.39 five August 2017 • the August 2017 Net proceeds to the Company were $24.8 Each share of Series D Preferred Stock has a stated value of $1,000 August 2017 $4.26 The conversion of the Series D Preferred Stock is subject to a beneficial ownership limitation of 9.99% August 2017 may 61 Prior to declaring any dividend or other distribution of its assets to holders of common stock, the Company shall first $0.0001 Unless and until converted into common stock in accordance with its terms, the Series D Preferred Stock has no The Series D Preferred Stock is classified as permanent equity, as the Company controls all actions or events required to settle the optional conversion feature in shares. The August 2017 August 2017 which have been recorded as derivative liabilities. These warrants have been recognized at their fair value of $13.0 third 3 from the date of issuance through September 30, 2017 $12.0 $5.5 August 2017 $6.2 $0.2 $5.8 $12.0 $6.2 In the event of a Fundamental Transaction, the holders of the Series D Preferred Stock will have the right to receive the consideration receivable as a result of such Fundamental Transaction by a holder of the number of shares of common stock for which the Series D Preferred Stock is convertible immediately prior to such Fundamental Transaction (without regard to whether such Series D Preferred Stock is convertible at such time), which amount shall be paid pari passu with all holders of common stock. A Fundamental Transaction is defined in the Certificate of Designation of Preferences, Rights and Limitations relating to the Series D Preferred Stock as any of the following: (i) merger with or consolidation into another legal entity; (ii) sale, lease, license, assignment, transfer or other disposition of all or substantially all of the Company’s assets in one 50% 50% Upon any liquidation, dissolution or winding-up of the Company, the holders of the Series D Preferred Stock shall be entitled to receive out of the assets of the Company the same amount that a holder of common stock would receive if the Series D Preferred Stock were fully converted to common stock immediately prior to such liquidation, dissolution or winding-up (without regard to whether such Series D Preferred Stock is convertible at such time), which amount shall be paid pari passu with all holders of common stock. The exercise price of the August 2017 three August 3, 2017 ( August 2017 The August 2017 $4.26, August 2017 five The effectiveness of the anti-dilution adjustment provision of the August 2017 August 2017 August 2017 September 30, 2017, none August 2017 August 2017 not In connection with the August 2017 not In connection with the August 2017 4.5%, one . Furthermore, Vivo will have the right to purchase additional shares of capital stock of the Company in connection with a sale of equity or equity-linked securities by the Company in a capital raising transaction for cash, subject to certain exceptions, to maintain its proportionate ownership percentage in the Company. Vivo agreed not August 2017 August 2018 . three August 2017 three no not, 33% one August 2017 August 2017 August 2017 The Company has agreed to solicit from its stockholders such approval as may August 2017 August 2017 August 2017 August 2017 August 2017 2018 August 2017 may, 90 2018 not August 2017 four August 2017 August 2017 August 2017 August 2017 August 2017 August 2017 no August 2017 may not August 2017 August 2017 August 2017 August 2017 August 2017 May 2017 In May 2017, 22,140 70,904 7,384,190 $7.80 7,384,190 $9.30 May 2017 May 2017 The net proceeds to the Company from the May 2017 $50.7 May 2017 $22.1 May 2017 $30.7 $40.2 $33.1 Series A Preferred Stock Each share of Series A Preferred Stock has a stated value of $1,000 $17.25 not October 9, 2017, 90th May 2017 Dividends, at a rate per year equal to 17.38% tenth October 15 April 15, October 15, 2017, tenth $1,738 $1,000 not first Unless and until converted into common stock in accordance with its terms, the Series A Preferred Stock has no Upon any liquidation, dissolution or winding-up of the Company, the holders of the Series A Preferred Stock shall be entitled to receive out of the assets of the Company the same amount that a holder of Common Stock would receive if the Series A Preferred Stock were fully converted to common stock immediately prior to such liquidation, dissolution or winding-up (without regard to whether such Series A Preferred Stock is convertible at such time), which amount shall be paid pari passu with all holders of Common Stock. The conversion of the Series A Preferred Stock is subject to a beneficial ownership limitation of 4.99% not 9.99%, not 61 May 2017 May 2017 not 3,792,778 May 2017 The Series A Preferred Stock is classified as permanent equity, as the Company controls all actions or events required to settle the optional and mandatory conversion feature in shares. The Make-Whole Payment was determined to be an embedded derivative requiring bifurcation and separate recognition as a derivative liability recognized at its fair value as of the issuance date with subsequent changes in fair value recorded in earnings until the Series A Preferred Stock is converted into common stock and the Make-Whole Payment is paid or until the Make-Whole Payment is paid through declared dividends or cash. A derivative liability was recognized at fair value on the date of issuance for the Make-Whole Payment in the amount of $11.0 $0.6 $0. As of September 30, 2017, 20,670 and there were 1,470 nine September 30, 2017, $10.0 in fair value of the derivative liabilities in connection with the 20,670 Series B Preferred Stock The Series B Preferred Stock has substantially identical terms to the Series A Preferred Stock, except that (i) the conversion of the Series B Preferred Stock was subject to the May 2017 May 2017 not September 30, 2017, June 30, 2017. “May 2017 July 2017 May 2017 May 2017 $12.8 The investors that purchased shares of the Series B Preferred Stock included related parties affiliated with members of the Board: Foris exchanged an aggregate principal amount of $27.0 30,729 May 2017 4,877,386 $2.0 2,333 May 2017 370,404 $8.6 The investors that purchased shares of the Series B Preferred Stock also included holders of certain of the Company's existing indebtedness, including the 2014 144A 2015 144A $3.4 2014 144A $3.7 2015 144A May 2017 May 2017 $1.9 Upon the closing of the May 2017 The Series B Preferred Stock issued to DSM in the May 2017 three September 30, 2017, May 2017 no $0.6 not As of September 30, 2017, 53,942 August 2017 41,962 $34.7 September 30, 2017 $1.2 $1.0 May 2017 nine September 30, 2017, $16.6 53,942 May 2017 The Company issued to each investor in the May 2017 100% 14,768,380 May 2017 May 2017 three May 2017 May 2017 September 30, 2017, May 2017 $4.40 September 30, 2017, no May 2017 In addition, the Company issued to each investor a warrant, with an exercise price of $0.0015 September 30, 2017 May 2017 May 2017 $6.30, September 30, 2017, May 2017 6,377,466 1,722,042 September 30, 2017. The exercise of the May 2017 May 2017 May 2017 May 2017 five May 2017 May 2017 May 2017 May 2017 May 2017 $39.5 September 30, 2017, May 2017 $27.0 third three nine September 30, 2017, $6.1 $12.5 May 2017 May 2017 July 2022. The full-ratchet anti-dilution protection of the May 2017 $4.4 September 30, 2017, May 2017 $21.7 three nine September 30, 2017, $19.0 $20.9 July 2022. Warrant activity and balances in connection with the May August 2017 Issued Exercised Warrants May and August 2017 Cash Warrants May 2017 14,768,380 — 14,768,380 August 2017 9,543,234 — 9,543,234 24,311,614 — 24,311,614 May and August 2017 Dilution Warrants May 2017 6,377,466 (1,722,042 ) 4,655,424 August 2017 — — — 6,377,466 (1,722,042 ) 4,655,424 Grand total 30,689,080 (1,722,042 ) 28,967,038 May 2017 In connection with the May 2017 May 2017 May 2017 May 2017 July 10, 2017, May 2017 May 2017 July 7, 2017. May 2017 In May 2017, May 2017 1,394,706 20,921 $0.0001 not May 2017 Each share of Series C Preferred Stock has a stated value of $1,000 $15.00 The Series C Preferred Stock is entitled to participate with the common stock on an as-converted basis with respect to any dividends or other distributions to holders of common stock. The Series C Preferred Stock shall vote together as one Upon any liquidation, dissolution or winding-up of the Company, the holders of the Series C Preferred stock shall be entitled to receive out of the assets of the Company an amount equal to the greater of (i) the par value of each share of Series C Preferred Stock, plus any accrued and unpaid dividends or other amounts due on such Series C Preferred Stock, prior to any distribution or payment to the holders of common stock or (ii) the amount that a holder would receive if the Series C Preferred Stock were fully c The shares of Series C Preferred Stock automatically converted to common stock on June 6, 2017 May 2017 no Exchange Agreement Warrants Under the 2015 2015 • Total received a warrant to purchase 1,261,613 September 30, 2017. • Total received a warrant to purchase 133,334 March 1, 2017, March 1, 2017, not March 1, 2017 September 30, 2017, not • Temasek received a warrant to purchase 978,525 September 30, 2017. • Temasek received a warrant exercisable for that number of shares of common stock equal to 58,690 133,334 September 30, 2017, not • Temasek received a warrant exercisable for that number of shares of common stock equal to ( 1 may 2015 133,334, 30.6% 69.4% 2 2014 144A may 13.3% 86.7% September 30, 2017, 846,683 1,889,986 The warrants issued to Total in the 2015 five 2015 ten $0.15 September 30, 2017. In addition to the grant of the warrants in the 2015 66,667 October 2013 2015 September 30, 2017, July 2015 In July 2015, 1,068,379 $23.40 $25.0 July 29, 2015. $0.15 September 30, 2017, 10% September 17, 2015. September 30, 2017, 25,643 81,197 At Market Issuance Sales Agreement On March 8, 2016, may $50.0 3 No. 333 203216 April 15, 2015. 415 one may not 3.0% no During the nine September 30, 2017, not $50.0 |
Note 8 - Commitments and Contin
Note 8 - Commitments and Contingencies | 9 Months Ended |
Sep. 30, 2017 | |
Notes to Financial Statements | |
Contingencies Disclosure [Text Block] | 8. Commitments Leases The Company leases certain facilities and finances certain equipment under operating and capital leases, respectively. Operating leases include leased facilities, and capital leases include leased equipment (see Note 4, February 2031. $1.4 and $1.3 for the three September 30, 2017 2016, $4.1 and $4.0 for the nine September 30, 2017 2016, Future minimum payments under the Company's lease obligations as of September 30, 2017 Years ending December 31: Capital Operating Total Lease 2017 (remaining three months) $ 307 $ 2,278 $ 2,585 2018 645 9,163 9,808 2019 75 7,790 7,865 2020 — 7,012 7,012 2021 — 7,248 7,248 Thereafter — 10,991 10,991 Total future minimum payments $ 1,027 $ 44,482 $ 45,509 Less: amount representing interest (37 ) Present value of minimum lease payments 990 Less: current portion (863 ) Long-term portion $ 127 Contingencies The Company's management assesses contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may If the assessment of a contingency indicates that it is probable that a loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company's financial statements. If the assessment indicates that a potential loss contingency is not not The Company has levied indirect taxes on sugarcane-based biodiesel sales by Amyris Brasil to customers in Brazil based on advice from external legal counsel. In the absence of definitive rulings from the Brazilian tax authorities on the appropriate indirect tax rate to be applied to such product sales, the actual indirect rate to be applied to such sales could differ from the rate we levied. In April 2017, March 2, 2017 April 17, 2017. March 2, 2017 12b 25 April 3, 2017. September 21, 2017, Subsequent to the filing of the securities class action complaint described above, four No. 4:17 04719, August 15, 2017, No. 3:17 04927, August 24, 2017. September 19, 2017, No. 2:15 04719, November 3, 2017. November 3, 2017, two No. 665782, June 20, 2017, No. 17865966, June 29, 2017, August 31, 2017, RG17876383. Given the early stage of these proceedings, it is not The Company is subject to disputes and claims that arise or have arisen in the ordinary course of business and that have not not may not one |
Note 9 - Noncontrolling Interes
Note 9 - Noncontrolling Interests | 9 Months Ended |
Sep. 30, 2017 | |
Notes to Financial Statements | |
Equity Method Investments and Joint Ventures Disclosure [Text Block] | 9. Aprinnova JV The Company is a 50% 810, The table below reflects the carrying amount of the Aprinnova JV's assets and liabilities, for which the Company is the primary beneficiary at September 30, 2017 September 30, 2017 December 31, 2016 Assets 33,385 30,778 Liabilities 3,192 333 Aprinnova JV's creditors have recourse only to the assets of Aprinnova JV. The change in the Company's noncontrolling interest in Aprinnova JV for the nine September 30, 2017 2016, 2017 2016 Balance at January 1 $ 937 $ — Acquisition of noncontrolling interest — 114 Net loss attributable to noncontrolling interest — — Balance at September 30 $ 937 $ 114 |
Note 10 - Significant Revenue A
Note 10 - Significant Revenue Agreements | 9 Months Ended |
Sep. 30, 2017 | |
Notes to Financial Statements | |
Collaborative Arrangement Disclosure [Text Block] | 10. Product Sales Nenter Agreements In 2016, December 31, 2020 5 Under this agreement, the Company recognized product revenues of $1.7 $2.8 three September 30, 2017 2016 , respectively, and $10.6 $2.8 nine September 30, 2017 2016 , respectively. In October 2016, May 2017. $2.5 August 2017, nine September 30, 2017. Grants and Collaborations DSM Collaboration and Licensing Agreements In July September 2017, three three In $9.0 one $9.0 October 2017. In addition, in connection with the entry into the DSM Collaboration Agreements, the Company and DSM entered into the DSM Credit Letter, pursuant to which the Company granted a credit to DSM in an aggregate amount of $12.0 not $6.0 2018. The DSM Credit Letter had a fair value of $7.1 August 2017 August 2017 August 2017 7, 605 50, As a result, the total fair value of $33.3 August 2017 August 2017 August 2017 $34.0 August 2017 $0.7 September 30, 2017, $7.1 See Note 15, September 30, 2017. Givaudan Agreements In 2016, entered into a Collaboration Agreement with Givaudan to establish a collaboration for the development and commercialization of certain renewable compounds for use in the fields of active cosmetics and flavors (the Givaudan Collaboration Agreement). Previously, in 2015, a separate ingredient. Under the Givaudan Collaboration Agreement, Givaudan agreed to pay to the Company $12.0 $3.0 June 30, 2016; September 30, 2017, $9.0 $1.5 $1.6 three September 30, 2017 2016 , respectively, and $4.5 $1.6 nine September 30, 2017 2016 , respectively, and (ii) product revenues under the Givaudan Supply Agreement of $1.3 $0 three September 30, 2017 2016 , respectively, and $2.0 $0 nine September 30, 2017 2016 , respectively. DARPA Technology Investment Agreement In 2015, five and is being funded by DARPA on a milestone basis . $1.3 $1.3 three September 30, 2017 2016 , respectively, and $6.9 $4.8 nine September 30, 2017 2016 , respectively. Firmenich Agreements In 2013, 2014, Firmenich Supply Agreement (the Firmenich Agreements) In July 2017, the 70/30 70% two 70/30 70% $15.0 50/50 not The Company recognized (i) collaboration revenues of $1.4 $1.3 three September 30, 2017 2016 , respectively, and $4.6 $5.5 nine September 30, 2017 2016 , respectively, and (ii) product revenues of $4.8 $0.3 three September 30, 2017 2016 , respectively, and $6.9 $5.2 nine September 30, 2017 2016 , respectively, under the Firmenich Agreements. Pursuant to the Firmenich Collaboration Agreement, the Company agreed to pay a one $2.5 not September 30, 2017 . one Michelin and Braskem Collaboration Agreements In 2011, 2011 $5.0 In June 2014, June 2014 June 2014 2011 June 2014 $5.0 $4.5 June 2014 $2.0 2014 $2.5 2015. In accordance with a September 2015 June 2014 The Company recognized collaboration revenues of $6.3 $0 three September 30, 2017 2016 , respectively, and $6.3 $0.1 nine September 30, 2017 2016 , , under the June 2014 . |
Note 11 - Stock-based Compensat
Note 11 - Stock-based Compensation | 9 Months Ended |
Sep. 30, 2017 | |
Notes to Financial Statements | |
Disclosure of Compensation Related Costs, Share-based Payments [Text Block] | 11. The Company’s stock option activity and related information for the nine September 30, 2017 Quantity of Weighted- Weighted-average Aggregate Outstanding - December 31, 2016 875,021 $ 55.20 Options granted 211,433 $ 6.64 Options exercised (133 ) $ 4.20 Options forfeited (137,298 ) $ 28.90 Outstanding - September 30, 2017 949,023 $ 48.19 6.7 $ 3,140 Vested and expected to vest after September 30, 2017 867,218 $ 51.73 6.5 $ 2,222 Exercisable at September 30, 2017 558,589 $ 72.64 5.2 $ — The Company’s restricted stock units (or "RSUs") and restricted stock activity and related information for the nine September 30, 2017 Quantity of Weighted- Weighted Outstanding - December 31, 2016 454,923 $ 17.48 Awarded 381,204 $ 6.46 Vested (155,849 ) $ 19.54 Forfeited (80,853 ) $ 13.85 Outstanding - September 30, 2017 599,425 $ 10.43 1.5 Expected to vest after September 30, 2017 460,278 $ 10.74 1.4 Stock-based Compensation Expense Stock-based compensation expense related to options and restricted stock units granted to employees and non-employees was allocated to research and development expense and sales, general and administrative expense as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Research and development $ 395 $ 481 $ 1,320 $ 1,457 Sales, general and administrative 863 1,327 2,622 4,188 Total stock-based compensation expense $ 1,258 $ 1,808 $ 3,942 $ 5,645 As of September 30, 2017, $6.9 2.7 Stock-based compensation expense for RSUs is measured based on the closing fair market value of the Company's common stock on the date of grant. Stock-based compensation expense for stock options and employee stock purchase plan rights is estimated at the grant date and offering date, respectively, based on their fair-value using the Black-Scholes option pricing model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of employee stock options was estimated using the following weighted-average assumptions: Three Months Ended Nine Months Ended 2017 2016 2017 2016 Expected dividend yield — % — % — % — % Risk-free interest rate 2.0 % 1.2 % 2.0 % 1.3 % Expected term (in years) 6.2 6.2 6.1 6.2 Expected volatility 92.2 % 76.7 % 81.6 % 73.0 % |
Note 12 - Related Party Transac
Note 12 - Related Party Transactions | 9 Months Ended |
Sep. 30, 2017 | |
Notes to Financial Statements | |
Related Party Transactions Disclosure [Text Block] | 12. Related Party Financings and Debt See Note 5, three nine September 30, 2017. Related Party Revenues For the three nine September 30, 2017 2016, Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 DSM $ 1,337 $ — $ 1,486 $ — Novvi — 1,390 — 1,390 TOTAL 77 — 77 — $ 1,414 $ 1,390 $ 1,563 $ 1,390 Related party accounts receivable balances as of September 30, 2017 December 31, 2016, $10.1 $0.9 Novvi Joint Venture In June 2017, $60,000 Pilot Plant Agreements with Total The Company and Total are parties to two five April 4, 2014 February 2017, not May 1, 2016, September 30, 2017 December 31, 2016, $1.6 $1.8 |
Note 13 - Income Taxes
Note 13 - Income Taxes | 9 Months Ended |
Sep. 30, 2017 | |
Notes to Financial Statements | |
Income Tax Disclosure [Text Block] | 13. The Company recorded income tax provisions as follows (in millions): Three Months Ended Nine Months Ended 2017 2016 2017 2016 Benefit from (provision for) income taxes $ 0.3 $ (0.1 ) $ — $ (0.4 ) The amounts for all periods presented are comprised of accrued Brazilian withholding tax on interest on intercompany loans. Other than those amounts, no three nine September 30, 2017 |
Note 14 - Net Loss Per Share At
Note 14 - Net Loss Per Share Attributable to Common Stockholders | 9 Months Ended |
Sep. 30, 2017 | |
Notes to Financial Statements | |
Earnings Per Share [Text Block] | 14. Basic net loss per share attributable to common stockholders is computed by dividing the Company’s net loss attributable to Amyris, Inc. common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share attributable to common stockholders is computed by giving effect to all potentially dilutive securities, including stock options, restricted stock units, common stock warrants and convertible promissory notes using the treasury stock method or the as-converted method, as applicable. For the three September 30, 2017 September 30, 2016, nine September 2017, $35.4 The following table presents the calculation of basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share amounts): Three Months Ended Nine Months Ended 2017 2016 2017 2016 Numerator: Net income (loss) attributable to Amyris, Inc. $ (33,861 ) $ (19,704 ) $ (70,612 ) $ (48,579 ) Less deemed dividend on capital distribution to related parties — — (8,648 ) — Less deemed dividend related to beneficial conversion feature on Series A preferred stock — — (562 ) — Less deemed dividend related to beneficial conversion feature on Series B preferred stock (634 ) — (634 ) — Less deemed dividend related to beneficial conversion feature on Series D preferred stock (5,757 ) — (5,757 ) — Less cumulative dividends on Series A and Series B preferred stock (2,567 ) — (4,242 ) — Net loss attributable to Amyris, Inc. common stockholders, basic (42,819 ) (19,704 ) (90,455 ) (48,579 ) Interest on convertible debt — — — 5,093 Accretion of debt discount — — — 5,304 Gain from change in fair value of derivative instruments — — (35,443 ) (37,593 ) Net loss attributable to Amyris, Inc. common stockholders, diluted $ (42,819 ) $ (19,704 ) $ (125,898 ) $ (75,775 ) Denominator: Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic 37,529,694 16,612,690 27,280,894 15,118,144 Basic loss per share $ (1.14 ) $ (1.19 ) $ (3.32 ) $ (3.21 ) Weighted-average shares of common stock outstanding 37,529,694 16,612,690 27,280,894 15,118,144 Effective of dilutive convertible promissory notes — — — 2,773,531 Weighted-average common stock equivalents used in computing net loss per share of common stock, diluted 37,529,694 16,612,690 27,280,894 17,891,675 Diluted loss per share $ (1.14 ) $ (1.19 ) $ (4.61 ) $ (4.24 ) The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share of common stock because including them would have been antidilutive: Three Months Ended Nine Months Ended 2017 2016 2017 2016 Period-end stock options to purchase common stock 949,023 924,062 949,023 924,062 Convertible promissory notes (1) 8,133,594 4,431,610 8,133,594 1,584,026 Period-end common stock warrants 31,303,080 977,561 31,303,080 977,561 Period-end restricted stock units 599,425 498,304 599,425 498,304 Total potentially dilutive securities excluded from computation of diluted net loss per share 40,985,122 6,831,537 40,985,122 3,983,953 ______________ ( 1 The potentially dilutive effect of convertible promissory notes was computed based on conversion ratios in effect as of the respective period end dates. A portion of the convertible promissory notes issued carries a provision for a reduction in conversion price under certain circumstances, which could potentially increase the dilutive shares outstanding. Another portion of the convertible promissory notes issued carries a provision for an increase in the conversion rate under certain circumstances, which could also potentially increase the dilutive shares outstanding. |
Note 15 - Subsequent Events
Note 15 - Subsequent Events | 9 Months Ended |
Sep. 30, 2017 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | 15. Additional Agreements with DSM On November 17, 2017, • DSM agreed to purchase 100% $30.7 first 1 1 • The Company will borrow $25.0 ◦ amounts outstanding under the Guanfu Note, and ◦ certain other outstanding indebtedness of Amyris Brasil, which amount will be deducted from the purchase price; • DSM will pay the Company an upfront license fee of $27.5 November 2017; • The Company and DSM will enter into other commercial agreements. The closing of the transactions described above is subject to several conditions, including the execution, delivery and assignment of certain agreements and contracts, obtaining certain third may not March 31, 2018. Additional Agreements with Ginkgo On November 13, 2017, • The Ginkgo Partnership Agreement (which supersedes the Ginkgo Collaboration Agreement), whereby the Company and Ginkgo agreed to: ◦ continue to collaborate on limited research and development; ◦ provide each other licenses (with royalties) to specified intellectual property for limited purposes; ◦ share in the net profits from sales of a certain product to be developed under the Ginkgo Partnership Agreement on a 50/50 December 31, 2018 September 30, 2022, November 2017 ◦ the Company will pay Ginkgo $500,000 The Ginkgo Partnership Agreement provides for an initial term of two one • The Company issued to Ginkgo an unsecured promissory note (Ginkgo Note) for $12.0 10.5% October 19, 2022. Biolding Note Amendment On November 13, 2017, November 15, 2017 December 31, 2017. |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 9 Months Ended |
Sep. 30, 2017 | |
Accounting Policies [Abstract] | |
Basis of Accounting, Policy [Policy Text Block] | Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (GAAP) and applicable rules and regulations of the Securities and Exchange Commission regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. As such, the information included in this quarterly report on Form 10 10 December 31, 2016. The condensed consolidated balance sheet as of December 31, 2016 not not December 31, 2017. There have been no 10 December 31, 2016 The accompanying interim condensed consolidated financial statements and related disclosures are unaudited, have been prepared on the same basis as the annual consolidated financial statements, and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the results of operations for the periods presented. In the nine September 30, 2017 • ASU 2015 11, Inventory (Topic 330 • ASU 2016 06, Derivatives and Hedging (Topic 815 • ASU 2016 09, Compensation—Stock Compensation (Topic 718 None |
Use of Estimates, Policy [Policy Text Block] | Use of Estimates The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the periods reported. Actual results could differ from these estimates, and such differences may |
Reverse Stock Split [Policy Text Block] | Reverse Stock Split On June 5, 2017, 1 15 $0.0001 500,000,000 250,000,000. first first may The par value, number of shares outstanding and number of authorized shares of preferred stock were not |
Note 3 - Fair Value Measureme25
Note 3 - Fair Value Measurement (Tables) | 9 Months Ended |
Sep. 30, 2017 | |
Notes Tables | |
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] | September 30, 2017 December 31, 2016 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets Money market funds $ 12,000 $ — $ — $ 12,000 $ 1,549 $ — $ — $ 1,549 Certificates of deposit 1,943 — — 1,943 1,373 — — 1,373 Total assets measured and recorded at fair value $ 13,943 $ — $ — $ 13,943 $ 2,922 $ — $ — $ 2,922 Liabilities Embedded derivatives in connection with the issuance of debt and equity instruments $ — $ — $ 21,069 $ 21,069 $ — $ — $ 4,135 $ 4,135 Freestanding derivative instruments in connection with the issuance of equity instruments — — 66,673 66,673 — — — — Currency interest rate swap derivative liability — 2,552 — 2,552 — 3,343 — 3,343 Total liabilities measured and recorded at fair value $ — $ 2,552 $ 87,742 $ 90,294 $ — $ 3,343 $ 4,135 $ 7,478 |
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] | 2017 2016 Balance at January 1 $ 4,136 $ 46,430 Gain from change in fair value of derivative liabilities (14,190 ) — Additions 129,492 (2,734 ) Derecognition upon conversion or extinguishment (31,696 ) (39,869 ) Balance at September 30 $ 87,742 $ 3,827 |
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block] | September 30, 2017 December 31, 2016 Risk-free interest rate 1.32% - 2.33% 0.55% - 1.31% Risk-adjusted yields 19.40% - 29.53% 12.80% - 22.93% Stock price volatility 45% - 80% 45% Probability of change in control 5% 5% Stock price $3.20 $3.93 $10.95 Credit spread 18.04% - 28.13% 11.59% - 21.64% Estimated conversion dates 2017 - 2022 2017 - 2019 |
Derivative Instruments, Gain (Loss) [Table Text Block] | Three Months Ended Nine Months Ended Type of derivative contract 2017 2016 2017 2016 Embedded derivatives and freestanding financial instruments in connection with the issuance of debt and equity $ (3,107 ) $ (624 ) $ 34,911 $ 39,869 Currency interest rate swaps 415 (162 ) 511 1,957 Total gain (loss) from change in fair value of derivative instruments $ (2,692 ) $ (786 ) $ 35,422 $ 41,826 |
Note 4 - Balance Sheet Compon26
Note 4 - Balance Sheet Components (Tables) | 9 Months Ended |
Sep. 30, 2017 | |
Notes Tables | |
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] | September 30, December 31, Accounts receivable $ 15,462 $ 13,583 Related party accounts receivable 10,102 895 25,564 14,478 Less: allowance for doubtful accounts (642 ) (501 ) Accounts receivable, net $ 24,922 $ 13,977 |
Schedule of Inventory, Current [Table Text Block] | September 30, December 31, Raw materials $ 3,236 $ 3,159 Work-in-process 885 1,848 Finished goods 2,289 1,206 Inventories $ 6,410 $ 6,213 |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] | September 30, 2017 December 31, 2016 Prepayments, advances and deposits $ 7,149 $ 3,727 Prepaid insurance 970 645 Other 1,125 1,711 Prepaid expenses and other current assets $ 9,244 $ 6,083 |
Property, Plant and Equipment [Table Text Block] | September 30, 2017 December 31, 2016 Machinery and equipment $ 88,532 $ 82,688 Leasehold improvements 39,150 38,785 Computers and software 9,898 9,585 Buildings 4,834 4,699 Construction in progress 259 2,216 Furniture and office equipment, vehicles and land 2,985 2,957 145,658 140,930 Less: accumulated depreciation and amortization (95,528 ) (87,195 ) Property, plant and equipment, net $ 50,130 $ 53,735 |
Schedule of Other Assets, Noncurrent [Table Text Block] | September 30, 2017 December 31, 2016 Cost-method investment in SweeGen $ 3,233 $ — Deposits 2,516 409 Goodwill 560 560 Other 1,361 1,366 Other assets $ 7,670 $ 2,335 |
Schedule of Accrued and Other Current Liabilities [Table Text Block] | September 30, December 31, Payroll and related expenses $ 6,549 $ 6,344 Accrued interest 5,586 4,847 SMA relocation accrual 4,554 3,641 Tax-related liabilities 3,575 2,610 Professional services 3,491 6,876 Other 5,128 5,792 Total accrued and other current liabilities $ 28,883 $ 30,110 |
Other Liabilities [Table Text Block] | September 30, December 31, Deferred rent, net of current portion $ 8,139 $ 8,906 Deferred revenue, net of current portion 3,744 6,650 Accrued interest, net of current portion 3,642 5,542 Capital lease obligation, net of current portion 111 334 Other liabilities 2,635 2,299 Total other liabilities $ 18,271 $ 23,731 |
Note 5 - Long-term Debt (Tables
Note 5 - Long-term Debt (Tables) | 9 Months Ended |
Sep. 30, 2017 | |
Notes Tables | |
Schedule of Debt [Table Text Block] | September 30, 2017 December 31, 2016 Convertible notes 2015 Rule 144A convertible notes $ 31,108 $ 22,766 2014 Rule 144A convertible notes 18,544 22,010 August 2013 financing convertible notes 1,042 9,247 Fidelity notes — 14,983 December 2016 and June 2017 amended notes — 9,975 50,694 78,981 Related party convertible notes August 2013 financing convertible notes 22,290 21,814 2014 Rule 144A convertible notes 21,417 17,320 R&D note 3,663 3,620 47,370 42,754 Loans payable Senior secured loan facility 28,156 27,658 Guanfu credit facility 20,446 19,564 Nossa Caixa and Banco Pine notes 9,917 11,136 Other loans payable 5,283 15,391 Other credit facilities 779 1,868 64,581 75,617 Related party loans payable February 2016 related party private placement 2,000 18,691 Other related party loans payable — 11,000 2,000 29,691 Total debt 164,645 227,043 Less: current portion (11,704 ) (59,155 ) Long-term debt, net of current portion $ 152,941 $ 167,888 |
Schedule of Long-term Debt Instruments [Table Text Block] | Years ending December 31: Convertible Related Loans Related Credit Total 2017 (remaining three months) $ 2,690 $ 803 $ 1,096 $ 2,487 $ 1,772 $ 8,848 2018 5,160 20,938 5,787 — 33,771 65,656 2019 69,339 35,298 2,766 — 2,580 109,983 2020 — — 2,656 — 2,500 5,156 2021 — — 2,544 — 27,396 29,940 Thereafter — — 4,115 — — 4,115 Total future minimum payments 77,189 57,039 18,964 2,487 68,019 223,698 Less: amount representing interest (1) (26,495 ) (9,669 ) (3,764 ) (487 ) (18,638 ) (59,053 ) Present value of minimum debt payments 50,694 47,370 15,200 2,000 49,381 164,645 Less: current portion — (3,700 ) (5,492 ) (2,000 ) (512 ) (11,704 ) Noncurrent portion of debt $ 50,694 $ 43,670 $ 9,708 $ — $ 48,869 $ 152,941 |
Note 6 - Mezzanine Equity (Tabl
Note 6 - Mezzanine Equity (Tables) | 9 Months Ended |
Sep. 30, 2017 | |
Notes Tables | |
Mezzanine Equity Table [Table Text Block] | September 30, December 31, Contingently redeemable common stock $ 5,000 $ 5,000 |
Note 7 - Stockholders' Deficit
Note 7 - Stockholders' Deficit (Tables) | 9 Months Ended |
Sep. 30, 2017 | |
Notes Tables | |
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] | Issued Exercised Warrants May and August 2017 Cash Warrants May 2017 14,768,380 — 14,768,380 August 2017 9,543,234 — 9,543,234 24,311,614 — 24,311,614 May and August 2017 Dilution Warrants May 2017 6,377,466 (1,722,042 ) 4,655,424 August 2017 — — — 6,377,466 (1,722,042 ) 4,655,424 Grand total 30,689,080 (1,722,042 ) 28,967,038 |
Note 8 - Commitments and Cont30
Note 8 - Commitments and Contingencies (Tables) | 9 Months Ended |
Sep. 30, 2017 | |
Notes Tables | |
Schedule Of Future Minimum Payments For Lease Obligations [Table Text Block] | Years ending December 31: Capital Operating Total Lease 2017 (remaining three months) $ 307 $ 2,278 $ 2,585 2018 645 9,163 9,808 2019 75 7,790 7,865 2020 — 7,012 7,012 2021 — 7,248 7,248 Thereafter — 10,991 10,991 Total future minimum payments $ 1,027 $ 44,482 $ 45,509 Less: amount representing interest (37 ) Present value of minimum lease payments 990 Less: current portion (863 ) Long-term portion $ 127 |
Note 9 - Noncontrolling Inter31
Note 9 - Noncontrolling Interests (Tables) | 9 Months Ended |
Sep. 30, 2017 | |
Notes Tables | |
Schedule of Variable Interest Entities [Table Text Block] | September 30, 2017 December 31, 2016 Assets 33,385 30,778 Liabilities 3,192 333 |
Noncontrolling Interest [Table Text Block] | 2017 2016 Balance at January 1 $ 937 $ — Acquisition of noncontrolling interest — 114 Net loss attributable to noncontrolling interest — — Balance at September 30 $ 937 $ 114 |
Note 11 - Stock-based Compens32
Note 11 - Stock-based Compensation (Tables) | 9 Months Ended |
Sep. 30, 2017 | |
Notes Tables | |
Schedule of Share-based Compensation, Stock Options and Stock Appreciation Rights Award Activity [Table Text Block] | Quantity of Weighted- Weighted-average Aggregate Outstanding - December 31, 2016 875,021 $ 55.20 Options granted 211,433 $ 6.64 Options exercised (133 ) $ 4.20 Options forfeited (137,298 ) $ 28.90 Outstanding - September 30, 2017 949,023 $ 48.19 6.7 $ 3,140 Vested and expected to vest after September 30, 2017 867,218 $ 51.73 6.5 $ 2,222 Exercisable at September 30, 2017 558,589 $ 72.64 5.2 $ — |
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block] | Quantity of Weighted- Weighted Outstanding - December 31, 2016 454,923 $ 17.48 Awarded 381,204 $ 6.46 Vested (155,849 ) $ 19.54 Forfeited (80,853 ) $ 13.85 Outstanding - September 30, 2017 599,425 $ 10.43 1.5 Expected to vest after September 30, 2017 460,278 $ 10.74 1.4 |
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] | Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Research and development $ 395 $ 481 $ 1,320 $ 1,457 Sales, general and administrative 863 1,327 2,622 4,188 Total stock-based compensation expense $ 1,258 $ 1,808 $ 3,942 $ 5,645 |
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | Three Months Ended Nine Months Ended 2017 2016 2017 2016 Expected dividend yield — % — % — % — % Risk-free interest rate 2.0 % 1.2 % 2.0 % 1.3 % Expected term (in years) 6.2 6.2 6.1 6.2 Expected volatility 92.2 % 76.7 % 81.6 % 73.0 % |
Note 12 - Related Party Trans33
Note 12 - Related Party Transactions (Tables) | 9 Months Ended |
Sep. 30, 2017 | |
Notes Tables | |
Schedule of Related Party Transactions [Table Text Block] | Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 DSM $ 1,337 $ — $ 1,486 $ — Novvi — 1,390 — 1,390 TOTAL 77 — 77 — $ 1,414 $ 1,390 $ 1,563 $ 1,390 |
Note 13 - Income Taxes (Tables)
Note 13 - Income Taxes (Tables) | 9 Months Ended |
Sep. 30, 2017 | |
Notes Tables | |
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] | Three Months Ended Nine Months Ended 2017 2016 2017 2016 Benefit from (provision for) income taxes $ 0.3 $ (0.1 ) $ — $ (0.4 ) |
Note 14 - Net Loss Per Share 35
Note 14 - Net Loss Per Share Attributable to Common Stockholders (Tables) | 9 Months Ended |
Sep. 30, 2017 | |
Notes Tables | |
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] | Three Months Ended Nine Months Ended 2017 2016 2017 2016 Numerator: Net income (loss) attributable to Amyris, Inc. $ (33,861 ) $ (19,704 ) $ (70,612 ) $ (48,579 ) Less deemed dividend on capital distribution to related parties — — (8,648 ) — Less deemed dividend related to beneficial conversion feature on Series A preferred stock — — (562 ) — Less deemed dividend related to beneficial conversion feature on Series B preferred stock (634 ) — (634 ) — Less deemed dividend related to beneficial conversion feature on Series D preferred stock (5,757 ) — (5,757 ) — Less cumulative dividends on Series A and Series B preferred stock (2,567 ) — (4,242 ) — Net loss attributable to Amyris, Inc. common stockholders, basic (42,819 ) (19,704 ) (90,455 ) (48,579 ) Interest on convertible debt — — — 5,093 Accretion of debt discount — — — 5,304 Gain from change in fair value of derivative instruments — — (35,443 ) (37,593 ) Net loss attributable to Amyris, Inc. common stockholders, diluted $ (42,819 ) $ (19,704 ) $ (125,898 ) $ (75,775 ) Denominator: Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic 37,529,694 16,612,690 27,280,894 15,118,144 Basic loss per share $ (1.14 ) $ (1.19 ) $ (3.32 ) $ (3.21 ) Weighted-average shares of common stock outstanding 37,529,694 16,612,690 27,280,894 15,118,144 Effective of dilutive convertible promissory notes — — — 2,773,531 Weighted-average common stock equivalents used in computing net loss per share of common stock, diluted 37,529,694 16,612,690 27,280,894 17,891,675 Diluted loss per share $ (1.14 ) $ (1.19 ) $ (4.61 ) $ (4.24 ) |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] | Three Months Ended Nine Months Ended 2017 2016 2017 2016 Period-end stock options to purchase common stock 949,023 924,062 949,023 924,062 Convertible promissory notes (1) 8,133,594 4,431,610 8,133,594 1,584,026 Period-end common stock warrants 31,303,080 977,561 31,303,080 977,561 Period-end restricted stock units 599,425 498,304 599,425 498,304 Total potentially dilutive securities excluded from computation of diluted net loss per share 40,985,122 6,831,537 40,985,122 3,983,953 |
Note 1 - The Company (Details T
Note 1 - The Company (Details Textual) - USD ($) | Aug. 07, 2017 | Aug. 03, 2017 | Aug. 31, 2017 | May 31, 2017 | May 31, 2017 | Sep. 30, 2017 | Sep. 30, 2016 | Dec. 31, 2016 |
Working Capital | $ (5,700,000) | $ (50,700,000) | ||||||
Retained Earnings (Accumulated Deficit) | (1,205,050,000) | (1,134,438,000) | ||||||
Cash, Cash Equivalents, and Short-term Investments | 17,600,000 | 28,500,000 | ||||||
Debt Instrument, Unamortized Discount | 23,700,000 | |||||||
Long-term Debt | 164,645,000 | 227,043,000 | ||||||
Long-term Debt, Current Maturities, Including Due to Related Parties | 11,704,000 | $ 59,155,000 | ||||||
Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months | 74,500,000 | |||||||
Interest Payable | 20,400,000 | |||||||
Debt Instrument, Original Principal, Extended Maturity | $ 21,000,000 | |||||||
Preferred Stock, Par or Stated Value Per Share | $ 0.0001 | $ 0.0001 | ||||||
Repayments of Long-term Debt | $ 26,708,000 | $ 7,442,000 | ||||||
Debt Instrument, Increase (Decrease), Net | $ 86,600,000 | |||||||
May 2017 Offering Closing [Member] | ||||||||
Proceeds from Issuance or Sale of Equity | $ 50,700,000 | |||||||
Securities Purchase Agreement [Member] | Vivo Capital LLC [Member] | ||||||||
Proceeds from Issuance or Sale of Equity | $ 24,800,000 | $ 25,900,000 | ||||||
Series A Preferred Stock [Member] | ||||||||
Preferred Stock, Dividend Rate, Percentage | 17.38% | |||||||
Preferred Stock, Par or Stated Value Per Share | $ 0.0001 | $ 0.0001 | ||||||
Series B Preferred Stock [Member] | ||||||||
Preferred Stock, Par or Stated Value Per Share | $ 0.0001 | $ 0.0001 | ||||||
Debt Conversion, Original Debt, Amount | $ 29,000,000 | $ 35,800,000 | ||||||
Series B Convertible Preferred Stock [Member] | DSM International B.V. [Member] | ||||||||
Proceeds from Issuance of Convertible Preferred Stock | $ 25,900,000 | $ 24,800,000 |
Note 2 - Summary of Significa37
Note 2 - Summary of Significant Accounting Policies (Details Textual) | Jun. 05, 2017$ / sharesshares | Sep. 30, 2017$ / sharesshares | Jun. 04, 2017shares | Dec. 31, 2016$ / sharesshares |
Common Stock, Par or Stated Value Per Share | $ / shares | $ 0.0001 | $ 0.0001 | $ 0.0001 | |
Common Stock, Shares Authorized | shares | 250,000,000 | 250,000,000 | 500,000,000 | 500,000,000 |
Reverse Stock Split [Member] | ||||
Stockholders' Equity Note, Stock Split, Conversion Ratio | 15 |
Note 3 - Fair Value Measureme38
Note 3 - Fair Value Measurement (Details Textual) $ in Thousands, BRL in Millions | Apr. 21, 2017USD ($)shares | Aug. 31, 2017 | Sep. 30, 2017USD ($) | Sep. 30, 2017BRL | Dec. 31, 2016USD ($) | Sep. 30, 2016USD ($) | Dec. 31, 2015USD ($) |
Loans Payable | $ 17,200 | ||||||
Long-term Line of Credit | 49,400 | ||||||
Convertible Debt | 98,100 | ||||||
Loans Payable, Fair Value Disclosure | 12,200 | ||||||
Line of Credit Facility, Fair Value of Amount Outstanding | 25,200 | ||||||
Convertible Debt, Fair Value Disclosures | 108,000 | ||||||
Long-term Debt | 164,645 | $ 227,043 | |||||
Fair Value Inputs, Discount Rate | 8.60% | ||||||
SweeGen Common Stock [Member] | |||||||
Equity Method Investment, Aggregate Cost | $ 3,200 | ||||||
Fair Value Inputs, Discount Rate | 40.00% | ||||||
Blue California [Member] | Intellectual Property License and Strain Access Agreement [Member] | SweeGen Common Stock [Member] | |||||||
Shares Received in Satisfaction of Payment Obligation | shares | 850,115 | ||||||
Banco Pine July 2012 Loan Agreement [Member] | Interest Rate Swap [Member] | |||||||
Derivative, Notional Amount | $ 6,900 | BRL 22 | |||||
Derivative, Fixed Interest Rate | 3.94% | 3.94% | |||||
The DSM Credit Letter [Member] | DSM International B.V. [Member] | |||||||
Long-term Debt | $ 7,100 | ||||||
Fair Value, Inputs, Level 3 [Member] | Derivative Liability, Compound Embedded Derivatives [Member] | |||||||
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value | 87,742 | 4,136 | $ 3,827 | $ 46,430 | |||
Derivative Liabilities [Member] | Fair Value, Inputs, Level 3 [Member] | Derivative Liability, Compound Embedded Derivatives [Member] | |||||||
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value | $ 87,700 | $ 4,100 |
Note 3 - Fair Value Measureme39
Note 3 - Fair Value Measurement - Fair Value, Assets, and Liabilities Measured on Recurring Basis (Details) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands | Sep. 30, 2017 | Dec. 31, 2016 |
Money market funds | $ 12,000 | $ 1,549 |
Certificates of deposit | 1,943 | 1,373 |
Total assets measured and recorded at fair value | 13,943 | 2,922 |
Embedded derivatives in connection with the issuance of debt and equity instruments | 21,069 | 4,135 |
Freestanding derivative instruments in connection with the issuance of equity instruments | 66,673 | |
Currency interest rate swap derivative liability | 2,552 | 3,343 |
Total liabilities measured and recorded at fair value | 90,294 | 7,478 |
Fair Value, Inputs, Level 1 [Member] | ||
Money market funds | 12,000 | 1,549 |
Certificates of deposit | 1,943 | 1,373 |
Total assets measured and recorded at fair value | 13,943 | 2,922 |
Fair Value, Inputs, Level 2 [Member] | ||
Money market funds | ||
Certificates of deposit | ||
Total assets measured and recorded at fair value | ||
Currency interest rate swap derivative liability | 2,552 | 3,343 |
Total liabilities measured and recorded at fair value | 2,552 | 3,343 |
Fair Value, Inputs, Level 3 [Member] | ||
Money market funds | ||
Certificates of deposit | ||
Total assets measured and recorded at fair value | ||
Embedded derivatives in connection with the issuance of debt and equity instruments | 21,069 | 4,135 |
Freestanding derivative instruments in connection with the issuance of equity instruments | 66,673 | |
Total liabilities measured and recorded at fair value | $ 87,742 | $ 4,135 |
Note 3 - Fair Value Measureme40
Note 3 - Fair Value Measurement - Reconciliation for Compound Embedded Derivative Liability (Details) - Fair Value, Inputs, Level 3 [Member] - Derivative Liability, Compound Embedded Derivatives [Member] - USD ($) $ in Thousands | 9 Months Ended | |
Sep. 30, 2017 | Sep. 30, 2016 | |
Balance, compound embedded derivative liabilities | $ 4,136 | $ 46,430 |
Gain from change in fair value of derivative liabilities | (14,190) | |
Additions | 129,492 | (2,734) |
Derecognition upon conversion or extinguishment | (31,696) | (39,869) |
Balance, compound embedded derivative liabilities | $ 87,742 | $ 3,827 |
Note 3 - Fair Value Measureme41
Note 3 - Fair Value Measurement - Market-based Assumption and Estimates for Compound Embedded Derivative Liabilities Valuation (Details) - $ / shares | 9 Months Ended | 12 Months Ended |
Sep. 30, 2017 | Dec. 31, 2016 | |
Expected volatility | 45.00% | |
Probability of change in control | 5.00% | 5.00% |
Share Price | $ 10.95 | |
Minimum [Member] | ||
Risk-free interest rate | 1.32% | 0.55% |
Risk-adjusted yields | 19.40% | 12.80% |
Expected volatility | 45.00% | |
Share Price | $ 3.20 | |
Credit spread | 18.04% | 11.59% |
Estimated conversion dates | 2,017 | 2,017 |
Maximum [Member] | ||
Risk-free interest rate | 2.33% | 1.31% |
Risk-adjusted yields | 29.53% | 22.93% |
Expected volatility | 80.00% | |
Share Price | $ 3.93 | |
Credit spread | 28.13% | 21.64% |
Estimated conversion dates | 2,022 | 2,019 |
Note 3 - Fair Value Measureme42
Note 3 - Fair Value Measurement - Derivative Instruments Classification (Details) - Gain (Loss) From Change in Fair Value of Derivative Instruments [Member] - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2017 | Sep. 30, 2016 | Sep. 30, 2017 | Sep. 30, 2016 | |
Embedded derivatives and freestanding financial instruments in connection with the issuance of debt and equity | $ (2,692) | $ (786) | $ 35,422 | $ 41,826 |
Embedded and Freestanding Derivative Financial Instruments [Member] | ||||
Embedded derivatives and freestanding financial instruments in connection with the issuance of debt and equity | (3,107) | (624) | 34,911 | 39,869 |
Currency Interest Rate Swap [Member] | ||||
Embedded derivatives and freestanding financial instruments in connection with the issuance of debt and equity | $ 415 | $ (162) | $ 511 | $ 1,957 |
Note 4 - Balance Sheet Compon43
Note 4 - Balance Sheet Components (Details Textual) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2017 | Sep. 30, 2016 | Sep. 30, 2017 | Sep. 30, 2016 | Dec. 31, 2016 | |
Property, Plant and Equipment, Gross | $ 145,658 | $ 145,658 | $ 140,930 | ||
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | 95,528 | 95,528 | 87,195 | ||
Depreciation, Depletion and Amortization | 8,124 | $ 8,561 | |||
Property, Plant and Equipment, Including Capital Leases [Member] | |||||
Depreciation, Depletion and Amortization | 2,700 | $ 2,900 | 8,100 | $ 8,600 | |
Capital Lease Obligations [Member] | |||||
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | 1,400 | 1,400 | 1,000 | ||
Capital Lease Obligations [Member] | Machinery and Equipment, Furniture and Office Equipment Under Capital Lease [Member] | |||||
Property, Plant and Equipment, Gross | $ 3,900 | $ 3,900 | $ 3,100 |
Note 4 - Balance Sheet Compon44
Note 4 - Balance Sheet Components - Accounts Receivable (Details) - USD ($) $ in Thousands | Sep. 30, 2017 | Dec. 31, 2016 |
Accounts receivable | $ 15,462 | $ 13,583 |
Related party accounts receivable | 10,102 | 895 |
25,564 | 14,478 | |
Less: allowance for doubtful accounts | (642) | (501) |
Accounts receivable, net | $ 24,922 | $ 13,977 |
Note 4 - Balance Sheet Compon45
Note 4 - Balance Sheet Components - Inventory, Current (Details) - USD ($) $ in Thousands | Sep. 30, 2017 | Dec. 31, 2016 |
Raw materials | $ 3,236 | $ 3,159 |
Work-in-process | 885 | 1,848 |
Finished goods | 2,289 | 1,206 |
Inventories | $ 6,410 | $ 6,213 |
Note 4 - Balance Sheet Compon46
Note 4 - Balance Sheet Components - Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands | Sep. 30, 2017 | Dec. 31, 2016 |
Prepayments, advances and deposits | $ 7,149 | $ 3,727 |
Prepaid insurance | 970 | 645 |
Other | 1,125 | 1,711 |
Prepaid expenses and other current assets | $ 9,244 | $ 6,083 |
Note 4 - Balance Sheet Compon47
Note 4 - Balance Sheet Components - Property, Plant and Equipment (Details) - USD ($) $ in Thousands | Sep. 30, 2017 | Dec. 31, 2016 |
Property, plant and equipment | $ 145,658 | $ 140,930 |
Less: accumulated depreciation and amortization | (95,528) | (87,195) |
Property, plant and equipment, net | 50,130 | 53,735 |
Machinery and Equipment [Member] | ||
Property, plant and equipment | 88,532 | 82,688 |
Leasehold Improvements [Member] | ||
Property, plant and equipment | 39,150 | 38,785 |
Computer Equipment and Software [Member] | ||
Property, plant and equipment | 9,898 | 9,585 |
Building [Member] | ||
Property, plant and equipment | 4,834 | 4,699 |
Construction in Progress [Member] | ||
Property, plant and equipment | 259 | 2,216 |
Furniture and Office Equipment, Vehicles and Land [Member] | ||
Property, plant and equipment | $ 2,985 | $ 2,957 |
Note 4 - Balance Sheet Compon48
Note 4 - Balance Sheet Components - Other Assets (Details) - USD ($) $ in Thousands | Sep. 30, 2017 | Dec. 31, 2016 |
Cost-method investment in SweeGen | $ 3,233 | |
Deposits | 2,516 | 409 |
Goodwill | 560 | 560 |
Other | 1,361 | 1,366 |
Other assets | $ 7,670 | $ 2,335 |
Note 4 - Balance Sheet Compon49
Note 4 - Balance Sheet Components - Accrued and Other Current Liabilities (Details) - USD ($) $ in Thousands | Sep. 30, 2017 | Dec. 31, 2016 |
Payroll and related expenses | $ 6,549 | $ 6,344 |
Accrued interest | 5,586 | 4,847 |
SMA relocation accrual | 4,554 | 3,641 |
Tax-related liabilities | 3,575 | 2,610 |
Professional services | 3,491 | 6,876 |
Other | 5,128 | 5,792 |
Total accrued and other current liabilities | $ 28,883 | $ 30,110 |
Note 4 - Balance Sheet Compon50
Note 4 - Balance Sheet Components - Other Liabilities (Details) - USD ($) $ in Thousands | Sep. 30, 2017 | Dec. 31, 2016 |
Deferred rent, net of current portion | $ 8,139 | $ 8,906 |
Deferred revenue, net of current portion | 3,744 | 6,650 |
Accrued interest, net of current portion | 3,642 | 5,542 |
Capital lease obligation, net of current portion | 111 | 334 |
Other liabilities | 2,635 | 2,299 |
Total other liabilities | $ 18,271 | $ 23,731 |
Note 5 - Long-term Debt (Detail
Note 5 - Long-term Debt (Details Textual) $ / shares in Units, BRL in Millions | Jun. 30, 2017USD ($) | Dec. 28, 2016USD ($) | Dec. 01, 2016USD ($) | Oct. 26, 2016USD ($) | Feb. 15, 2016USD ($)$ / sharesshares | Oct. 20, 2015USD ($) | Oct. 14, 2015$ / sharesshares | Jul. 29, 2015USD ($)$ / shares | May 31, 2017USD ($) | Apr. 30, 2017USD ($) | Feb. 28, 2017USD ($) | Jan. 31, 2017USD ($)shares | Dec. 31, 2016USD ($) | Jun. 30, 2016USD ($) | Jun. 30, 2014 | May 31, 2014USD ($) | Mar. 31, 2014USD ($) | Jan. 31, 2014USD ($) | Oct. 31, 2013USD ($) | Sep. 30, 2017USD ($)$ / sharesshares | Sep. 30, 2016USD ($) | Sep. 30, 2017USD ($)$ / sharesshares | Sep. 30, 2017BRL | Sep. 30, 2016USD ($) | Nov. 30, 2015USD ($) | Sep. 30, 2017BRLshares | Feb. 27, 2017 | Oct. 27, 2016USD ($) | Oct. 21, 2016USD ($) | Mar. 31, 2016USD ($) | Oct. 31, 2015USD ($) | Dec. 31, 2013USD ($) | Aug. 31, 2013USD ($) | Jul. 31, 2012 | Feb. 28, 2012USD ($)$ / shares |
Extinguishment of Debt, Amount | $ 40,200,000 | ||||||||||||||||||||||||||||||||||
Gain (Loss) on Extinguishment of Debt | $ (1,900,000) | $ 461,000 | $ (217,000) | $ (3,067,000) | $ (866,000) | ||||||||||||||||||||||||||||||
Long-term Debt | $ 227,043,000 | 164,645,000 | 164,645,000 | ||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount | 23,700,000 | 23,700,000 | |||||||||||||||||||||||||||||||||
Long-term Line of Credit | 49,400,000 | $ 49,400,000 | |||||||||||||||||||||||||||||||||
The February 2016 Warrants [Member] | |||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Term | 5 years | 5 years | |||||||||||||||||||||||||||||||||
Private Placement February 2016 [Member] | |||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 13.50% | ||||||||||||||||||||||||||||||||||
Private Placement February 2016 [Member] | Stegodon [Member] | |||||||||||||||||||||||||||||||||||
Debt Instrument, Fee Amount, Current | 425,000 | $ 425,000 | |||||||||||||||||||||||||||||||||
Debt Instrument, Fee Amount, Noncurrent | 450,000 | 450,000 | |||||||||||||||||||||||||||||||||
Private Placement February 2016 [Member] | Foris Ventures, LLC [Member] | |||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 152,381 | ||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Private Placement | $ 16,000,000 | ||||||||||||||||||||||||||||||||||
Private Placement February 2016 [Member] | Naxyris S.A. [Member] | |||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 19,048 | ||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Private Placement | $ 2,000,000 | ||||||||||||||||||||||||||||||||||
Private Placement February 2016 [Member] | Biolding Investment SA [Member] | |||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 19,048 | ||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Private Placement | $ 2,000,000 | ||||||||||||||||||||||||||||||||||
Nossa Caixa and Banco Pine Agreements [Member] | |||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | 16,400,000 | 16,400,000 | BRL 52 | ||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 5.50% | ||||||||||||||||||||||||||||||||||
Certain Farnesene Production Assets Pledged as Collateral for Loans | 16,400,000 | 16,400,000 | BRL 52 | ||||||||||||||||||||||||||||||||
Collateral Provided by Company Certain Equipment and Other Tangible Assets, Amount | 21,500,000 | BRL 68 | |||||||||||||||||||||||||||||||||
Temasek [Member] | |||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 71,000,000 | ||||||||||||||||||||||||||||||||||
Total [Member] | |||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 70,000,000 | ||||||||||||||||||||||||||||||||||
Total and Temasek [Member] | |||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 34.50 | ||||||||||||||||||||||||||||||||||
Maximum [Member] | Hercules Technology Growth Capital, Inc. (Hercules) [Member] | Prime Rate [Member] | |||||||||||||||||||||||||||||||||||
Debt Instrument, Basis Spread on Variable Rate | 9.50% | ||||||||||||||||||||||||||||||||||
Minimum [Member] | Hercules Technology Growth Capital, Inc. (Hercules) [Member] | Prime Rate [Member] | |||||||||||||||||||||||||||||||||||
Debt Instrument, Basis Spread on Variable Rate | 6.25% | ||||||||||||||||||||||||||||||||||
Related Party Convertible Notes [Member] | |||||||||||||||||||||||||||||||||||
Gain (Loss) on Extinguishment of Debt | $ (9,400,000) | ||||||||||||||||||||||||||||||||||
Long-term Debt | 42,754,000 | $ 47,370,000 | $ 47,370,000 | ||||||||||||||||||||||||||||||||
Related Party Convertible Notes [Member] | The Second Tranche [Member] | |||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 5.2977 | $ 5.2977 | |||||||||||||||||||||||||||||||||
Convertible Promissory Notes, Period After Which Notes Will Be Due | 5 years | ||||||||||||||||||||||||||||||||||
Convertible Notes Exchanged and Cancelled | $ 6,000,000 | ||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price, Interest Accrued | 10.00% | ||||||||||||||||||||||||||||||||||
Convertible Debt [Member] | |||||||||||||||||||||||||||||||||||
Long-term Debt | 78,981,000 | $ 50,694,000 | $ 50,694,000 | ||||||||||||||||||||||||||||||||
Unsecured Promissory Notes, 2016 [Member] | Private Placement February 2016 [Member] | |||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 20,000,000 | ||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 190,477 | ||||||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 0.15 | ||||||||||||||||||||||||||||||||||
Proceeds from Issuance of Private Placement | $ 20,000,000 | ||||||||||||||||||||||||||||||||||
Total [Member] | |||||||||||||||||||||||||||||||||||
Debt Instrument, Repurchase Amount | $ 3,700,000 | ||||||||||||||||||||||||||||||||||
Rule 144A Convertible Note Offering [Member] | |||||||||||||||||||||||||||||||||||
Proceeds from Convertible Debt | $ 72,000,000 | ||||||||||||||||||||||||||||||||||
Convertible Note Offering | $ 75,000,000 | ||||||||||||||||||||||||||||||||||
Rule 144A Convertible Note Offering [Member] | Denominator [Member] | |||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Rate, Principle Amount | $ / shares | $ 1,000 | ||||||||||||||||||||||||||||||||||
Rule 144A Convertible Note Offering [Member] | Reverse Stock Split [Member] | |||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 56.16 | $ 56.16 | |||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Ratio | 17.8073 | 17.8073 | |||||||||||||||||||||||||||||||||
Rule 144A Convertible Note Offering [Member] | Convertible Debt Securities [Member] | |||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 6.50% | ||||||||||||||||||||||||||||||||||
Rule 144A Convertible Note Offering [Member] | Affiliated Entity [Member] | |||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 57,600,000 | ||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 6.50% | ||||||||||||||||||||||||||||||||||
Amount of Convertible Debt Purchased by Affiliated Entities | $ 24,700,000 | ||||||||||||||||||||||||||||||||||
Debt Instrument, Repurchase Amount | $ 18,300,000 | ||||||||||||||||||||||||||||||||||
Debt Instrument, Repurchased Face Amount | 22,900,000 | ||||||||||||||||||||||||||||||||||
Rule 144A Convertible Note Offering [Member] | Total [Member] | |||||||||||||||||||||||||||||||||||
Debt Instrument, Decrease, Forgiveness | $ 9,700,000 | ||||||||||||||||||||||||||||||||||
Convertible Senior Notes, 9.5% [Member] | |||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 9.50% | ||||||||||||||||||||||||||||||||||
Proceeds from Convertible Debt | $ 54,400,000 | ||||||||||||||||||||||||||||||||||
Debt Instrument, Interest, Payable in Common Stock, Percentage of Market-based Price | 92.50% | 92.50% | 92.50% | ||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Rate, Shares | shares | 58.2076 | ||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Rate, Principle Amount | $ / shares | $ 1,000 | ||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 17.18 | ||||||||||||||||||||||||||||||||||
Convertible Note Substantial Change, Discount Rate Used in Calculate Value of Remaining Interest Payments | 0.75% | ||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible Percentage of Average Price Per Share the Stock will be Valued upon Early Conversion | 92.50% | ||||||||||||||||||||||||||||||||||
Convertible Promissory Note, Additional Principal Amount Issued During Period | $ 19,100,000 | ||||||||||||||||||||||||||||||||||
Debt Instrument, Decrease, Forgiveness | $ 15,300,000 | ||||||||||||||||||||||||||||||||||
Shares Issuable with Respect to Debt Instrument, Maximum Number of Shares of Common Stock Without Prior Approval | shares | 3,652,935 | ||||||||||||||||||||||||||||||||||
August 2013 Convertible Notes [Member] | Related Party Convertible Notes [Member] | |||||||||||||||||||||||||||||||||||
Long-term Debt | 21,814,000 | $ 22,290,000 | $ 22,290,000 | ||||||||||||||||||||||||||||||||
August 2013 Convertible Notes [Member] | Convertible Debt [Member] | |||||||||||||||||||||||||||||||||||
Long-term Debt | 9,247,000 | 1,042,000 | 1,042,000 | ||||||||||||||||||||||||||||||||
August 2013 Convertible Notes [Member] | Total and Temasek [Member] | |||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 73,000,000 | ||||||||||||||||||||||||||||||||||
First Tranche [Member] | Related Party Convertible Notes [Member] | |||||||||||||||||||||||||||||||||||
Proceeds from Convertible Debt | $ 7,600,000 | ||||||||||||||||||||||||||||||||||
Cancellation of Convertible Debt | 44,200,000 | ||||||||||||||||||||||||||||||||||
Gain (Loss) on Extinguishment of Debt | $ (19,900,000) | ||||||||||||||||||||||||||||||||||
Convertible Promissory Notes, Period After Which Notes Will Be Due | 5 years | ||||||||||||||||||||||||||||||||||
Plant Manufacturing Production, Product Sales, Percentage | 5.00% | ||||||||||||||||||||||||||||||||||
First Tranche [Member] | Total [Member] | Related Party Convertible Notes [Member] | |||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 51,800,000 | ||||||||||||||||||||||||||||||||||
Extinguishment of Debt, Amount | 9,200,000 | ||||||||||||||||||||||||||||||||||
First Tranche [Member] | Temasek [Member] | Related Party Convertible Notes [Member] | |||||||||||||||||||||||||||||||||||
Extinguishment of Debt, Amount | $ 35,000,000 | ||||||||||||||||||||||||||||||||||
Second Tranche [Member] | Wolverine [Member] | Related Party Convertible Notes [Member] | |||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 3,000,000 | ||||||||||||||||||||||||||||||||||
The Second Tranche [Member] | Related Party Convertible Notes [Member] | |||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 34,000,000 | ||||||||||||||||||||||||||||||||||
The Second Tranche [Member] | Related Party Convertible Notes [Member] | Temasek [Member] | |||||||||||||||||||||||||||||||||||
Convertible Notes Purchased | 25,000,000 | ||||||||||||||||||||||||||||||||||
The Second Tranche [Member] | Related Party Convertible Notes [Member] | Wolverine [Member] | |||||||||||||||||||||||||||||||||||
Convertible Notes Purchased | 3,000,000 | ||||||||||||||||||||||||||||||||||
The Second Tranche [Member] | Related Party Convertible Notes [Member] | Total [Member] | |||||||||||||||||||||||||||||||||||
Convertible Notes Purchased | $ 6,000,000 | ||||||||||||||||||||||||||||||||||
Fidelity Convertible Notes [Member] | |||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | 57,600,000 | ||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 106.02 | ||||||||||||||||||||||||||||||||||
Debt Instrument, Decrease, Forgiveness | $ 15,300,000 | ||||||||||||||||||||||||||||||||||
Debt Instrument, Repurchase Amount | 8,800,000 | ||||||||||||||||||||||||||||||||||
Debt Instrument, Repurchased Face Amount | $ 9,700,000 | ||||||||||||||||||||||||||||||||||
Gain (Loss) on Extinguishment of Debt | 100,000 | ||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 19,100,000 | ||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Exchange Ratio of Converted Debt to Original Debt | 1.25 | ||||||||||||||||||||||||||||||||||
Fidelity Convertible Notes [Member] | Convertible Subordinated Debt [Member] | |||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 3.00% | ||||||||||||||||||||||||||||||||||
Convertible Notes Payable | $ 25,000,000 | ||||||||||||||||||||||||||||||||||
Fidelity Convertible Notes [Member] | Convertible Debt [Member] | |||||||||||||||||||||||||||||||||||
Long-term Debt | 14,983,000 | ||||||||||||||||||||||||||||||||||
The December 2016 Convertible Note [Member] | Convertible Subordinated Debt [Member] | |||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 10,000,000 | ||||||||||||||||||||||||||||||||||
Proceeds from Convertible Debt | $ 9,900,000 | ||||||||||||||||||||||||||||||||||
The April 2017 Convertible Notes [Member] | Convertible Debt [Member] | Maximum [Member] | |||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 15,000,000 | ||||||||||||||||||||||||||||||||||
The April 2017 Convertible Notes, Initial Closing [Member] | Convertible Debt [Member] | |||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | 7,000,000 | ||||||||||||||||||||||||||||||||||
Proceeds from Convertible Debt | 6,900,000 | ||||||||||||||||||||||||||||||||||
The Amended Notes [Member] | |||||||||||||||||||||||||||||||||||
Convertible Debt Securities, Monthly Installment Discount | 20.00% | ||||||||||||||||||||||||||||||||||
Convertible Debt Securities, Price Floor Payment Discount Rate | 70.00% | ||||||||||||||||||||||||||||||||||
The Amended Notes [Member] | Convertible Debt [Member] | |||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 28.50 | $ 28.50 | |||||||||||||||||||||||||||||||||
Debt Instrument, Term | 1 year 180 days | 1 year 180 days | |||||||||||||||||||||||||||||||||
Debt Instrument, Monthly Installments, Percent of Installment Amount | 118.00% | 118.00% | |||||||||||||||||||||||||||||||||
Debt Instrument, Additional Common Stock Payment, Maximum Percent of Aggregate Amount | 50.00% | 50.00% | 50.00% | ||||||||||||||||||||||||||||||||
Debt Instrument, Threshold Amount of Dollar-weighted Volume of Common Stock | $ 200,000 | $ 200,000 | |||||||||||||||||||||||||||||||||
Debt Instrument, Events of Default, Percentage of Amount can be Redeemed by Holders | 118.00% | 118.00% | |||||||||||||||||||||||||||||||||
Convertible Debt, Beneficial Common Stock Ownership, Maximum Percentage Except Under Specified Conditions | 4.99% | 4.99% | 4.99% | ||||||||||||||||||||||||||||||||
Convertible Debt, Beneficial Common Stock Ownership, Maximum Percentage Under Specified Conditions | 9.99% | 9.99% | 9.99% | ||||||||||||||||||||||||||||||||
Convertible Debt, Beneficial Common Stock Ownership, Maximum Percentage, Conditions, Number of Days After Written Notice | 61 days | 61 days | |||||||||||||||||||||||||||||||||
Convertible Debt, Aggregate Number of Shares Issued With Respect to the Initial Closing, Maximum | shares | 3,645,118 | 3,645,118 | 3,645,118 | ||||||||||||||||||||||||||||||||
Long-term Debt | $ 0 | $ 0 | |||||||||||||||||||||||||||||||||
Debt Instrument, Additional Amount Available for Issuance | 5,000,000 | 5,000,000 | |||||||||||||||||||||||||||||||||
The 3 Million Note [Member] | |||||||||||||||||||||||||||||||||||
Proceeds from Convertible Debt | $ 3,000,000 | ||||||||||||||||||||||||||||||||||
Debt Instrument, Fee Amount | $ 3,000,000 | ||||||||||||||||||||||||||||||||||
Related Party Convertible Tranche Notes [Member] | |||||||||||||||||||||||||||||||||||
Long-term Debt, Gross | 19,800,000 | 21,200,000 | 21,200,000 | ||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Premium | 2,000,000 | 1,100,000 | 1,100,000 | ||||||||||||||||||||||||||||||||
Related Party 2014 144A Convertible Notes [Member] | |||||||||||||||||||||||||||||||||||
Long-term Debt, Gross | 24,700,000 | 24,700,000 | 24,700,000 | ||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount | 7,400,000 | $ 3,300,000 | $ 3,300,000 | ||||||||||||||||||||||||||||||||
Total Purchase Agreement [Member] | Total [Member] | |||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 105,000,000 | ||||||||||||||||||||||||||||||||||
Replacement Notes [Member] | |||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 46.20 | $ 46.20 | |||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 12.00% | 1.50% | |||||||||||||||||||||||||||||||||
Loan and Security Agreement [Member] | Hercules Technology Growth Capital, Inc. (Hercules) [Member] | |||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 25,000,000 | ||||||||||||||||||||||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 31,000,000 | ||||||||||||||||||||||||||||||||||
Proceeds from Long-term Lines of Credit | 16,000,000 | ||||||||||||||||||||||||||||||||||
Payments of Financing Costs | $ 1,500,000 | ||||||||||||||||||||||||||||||||||
Debt Instrument, Prepayment Price, Percentage of Principal Amount | 101.00% | 101.00% | 101.00% | ||||||||||||||||||||||||||||||||
Debt Instrument, Prepayment, End of Term Charge | $ 3,300,000 | $ 3,300,000 | |||||||||||||||||||||||||||||||||
Loan and Security Agreement [Member] | Stegodon [Member] | |||||||||||||||||||||||||||||||||||
Debt Instrument, Requirement, Maximum Monthly Repayment, Using Proceeds from Collaboration Agreement | $ 1,000,000 | ||||||||||||||||||||||||||||||||||
Debt Instrument, Additional Monies Agreed to Apply Toward Repayment of Outstanding Loans, Maximum | $ 3,000,000 | ||||||||||||||||||||||||||||||||||
Hercules Credit Additional Amount [Member] | Maximum [Member] | Hercules Technology Growth Capital, Inc. (Hercules) [Member] | Prime Rate [Member] | |||||||||||||||||||||||||||||||||||
Debt Instrument, Basis Spread on Variable Rate | 8.50% | ||||||||||||||||||||||||||||||||||
Hercules Credit Additional Amount [Member] | Minimum [Member] | Hercules Technology Growth Capital, Inc. (Hercules) [Member] | Prime Rate [Member] | |||||||||||||||||||||||||||||||||||
Debt Instrument, Basis Spread on Variable Rate | 5.25% | ||||||||||||||||||||||||||||||||||
Guanfu Credit Agreement [Member] | Unsecured Debt [Member] | Guanfu Holding Co., Ltd [Member] | |||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 10.00% | ||||||||||||||||||||||||||||||||||
Debt Instrument, Term | 5 years | ||||||||||||||||||||||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 25,000,000 | ||||||||||||||||||||||||||||||||||
Long-term Line of Credit | 25,000,000 | ||||||||||||||||||||||||||||||||||
Common Stock, Volume Weighted Average Closing Sale Price, Percentage | 90.00% | ||||||||||||||||||||||||||||||||||
Salisbury Note [Member] | Salisbury Partners, LLC [Member] | |||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 3,500,000 | ||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 5.00% | ||||||||||||||||||||||||||||||||||
Debt Instrument, Term | 13 years | ||||||||||||||||||||||||||||||||||
Nikko Note [Member] | Nikko [Member] | |||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 3,900,000 | ||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 5.00% | ||||||||||||||||||||||||||||||||||
Debt Instrument, Term | 13 years | ||||||||||||||||||||||||||||||||||
Debt Instrument, Delinquency Penalty | 5.00% | ||||||||||||||||||||||||||||||||||
Debt Instrument, Delinquency Penalty, Threshold | 5 days | ||||||||||||||||||||||||||||||||||
Debt Instrument, Percentage of Joint Venture Interests Owned By the Company Securing the Debt Instrument | 10.00% | ||||||||||||||||||||||||||||||||||
Debt Instrument, Additional Payments Required in Four Monthly Installments | $ 400,000 | ||||||||||||||||||||||||||||||||||
Debt Instrument, Additional Equal Monthly Installments, Amount | $ 100,000 | ||||||||||||||||||||||||||||||||||
Aprinnova Notes [Member] | Unsecured Debt [Member] | Aprinnova JV [Member] | |||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 1,500,000 | ||||||||||||||||||||||||||||||||||
Debt Instrument, Periodic Payment | $ 375,000 | ||||||||||||||||||||||||||||||||||
Aprinnova Notes [Member] | Unsecured Debt [Member] | Nikko [Member] | Aprinnova JV [Member] | |||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 2.75% | 2.75% | 2.75% | ||||||||||||||||||||||||||||||||
Second Aprinnova Loan [Member] | Unsecured Debt [Member] | Nikko [Member] | Aprinnova JV [Member] | |||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 1,500,000 | $ 1,500,000 | |||||||||||||||||||||||||||||||||
October 2016 Private Placement [Member] | Convertible Subordinated Debt [Member] | Ginkgo Bioworks [Member] | |||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 3,000,000 | $ 8,500,000 | |||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 13.50% | ||||||||||||||||||||||||||||||||||
October 2016 Private Placement [Member] | Convertible Subordinated Debt [Member] | Foris Ventures, LLC [Member] | |||||||||||||||||||||||||||||||||||
Debt Instrument, Face Amount | $ 11,000,000 | ||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 13.50% | ||||||||||||||||||||||||||||||||||
Rule 144A Convertible Notes [Member] | Temasek [Member] | |||||||||||||||||||||||||||||||||||
Convertible Notes Payable | $ 10,000,000 | ||||||||||||||||||||||||||||||||||
Rule 144A Convertible Notes [Member] | Total [Member] | |||||||||||||||||||||||||||||||||||
Convertible Notes Payable | $ 9,700,000 |
Note 5 - Long-term Debt - Debt
Note 5 - Long-term Debt - Debt Components (Details) - USD ($) $ in Thousands | Sep. 30, 2017 | Dec. 31, 2016 |
Debt | $ 164,645 | $ 227,043 |
Debt, current | (11,704) | (59,155) |
Debt, noncurrent | 152,941 | 167,888 |
Convertible Debt [Member] | ||
Debt | 50,694 | 78,981 |
Debt, noncurrent | 50,694 | |
Convertible Debt [Member] | The 2015 144A Notes [Member] | ||
Debt | 31,108 | 22,766 |
Convertible Debt [Member] | The 2014 144A Notes [Member] | ||
Debt | 18,544 | 22,010 |
Convertible Debt [Member] | August 2013 Convertible Notes [Member] | ||
Debt | 1,042 | 9,247 |
Convertible Debt [Member] | Fidelity Convertible Notes [Member] | ||
Debt | 14,983 | |
Convertible Debt [Member] | The December 2016 and June 2017 Convertible Notes [Member] | ||
Debt | 9,975 | |
Related Party Convertible Notes [Member] | ||
Debt | 47,370 | 42,754 |
Debt, noncurrent | 43,670 | |
Related Party Convertible Notes [Member] | The 2014 144A Notes [Member] | ||
Debt | 21,417 | 17,320 |
Related Party Convertible Notes [Member] | August 2013 Convertible Notes [Member] | ||
Debt | 22,290 | 21,814 |
Related Party Convertible Notes [Member] | Secured R&D Notes [Member] | ||
Debt | 3,663 | 3,620 |
Loans Payable [Member] | ||
Debt | 64,581 | 75,617 |
Debt, noncurrent | 9,708 | |
Loans Payable [Member] | Senior Secured Convertible Note [Member] | ||
Debt | 28,156 | 27,658 |
Loans Payable [Member] | Guanfu Credit Facility [Member] | ||
Debt | 20,446 | 19,564 |
Loans Payable [Member] | Nossa Caixa [Member] | ||
Debt | 9,917 | 11,136 |
Loans Payable [Member] | Other Loans Payable [Member] | ||
Debt | 5,283 | 15,391 |
Loans Payable [Member] | Other Credit Facilities [Member] | ||
Debt | 779 | 1,868 |
Related Party Loan Payable [Member] | ||
Debt | 2,000 | 29,691 |
Debt, noncurrent | ||
Related Party Loan Payable [Member] | Other Loans Payable [Member] | ||
Debt | 11,000 | |
Related Party Loan Payable [Member] | Private Placement February 2016 [Member] | ||
Debt | $ 2,000 | $ 18,691 |
Note 5 - Long-term Debt - Long-
Note 5 - Long-term Debt - Long-term Debt Instruments (Details) - USD ($) $ in Thousands | Sep. 30, 2017 | Dec. 31, 2016 | |
2017 (remaining three months) | $ 8,848 | ||
2,018 | 65,656 | ||
2,019 | 109,983 | ||
2,020 | 5,156 | ||
2,021 | 29,940 | ||
Thereafter | 4,115 | ||
Total future minimum payments | 223,698 | ||
Less: amount representing interest (1) | [1] | (59,053) | |
Present value of minimum debt payments | 164,645 | ||
Less: current portion | (11,704) | ||
Noncurrent portion of debt | 152,941 | $ 167,888 | |
Convertible Debt [Member] | |||
2017 (remaining three months) | 2,690 | ||
2,018 | 5,160 | ||
2,019 | 69,339 | ||
2,020 | |||
2,021 | |||
Thereafter | |||
Total future minimum payments | 77,189 | ||
Less: amount representing interest (1) | [1] | (26,495) | |
Present value of minimum debt payments | 50,694 | ||
Less: current portion | |||
Noncurrent portion of debt | 50,694 | ||
Related Party Convertible Notes [Member] | |||
2017 (remaining three months) | 803 | ||
2,018 | 20,938 | ||
2,019 | 35,298 | ||
2,020 | |||
2,021 | |||
Thereafter | |||
Total future minimum payments | 57,039 | ||
Less: amount representing interest (1) | [1] | (9,669) | |
Present value of minimum debt payments | 47,370 | ||
Less: current portion | (3,700) | ||
Noncurrent portion of debt | 43,670 | ||
Loans Payable [Member] | |||
2017 (remaining three months) | 1,096 | ||
2,018 | 5,787 | ||
2,019 | 2,766 | ||
2,020 | 2,656 | ||
2,021 | 2,544 | ||
Thereafter | 4,115 | ||
Total future minimum payments | 18,964 | ||
Less: amount representing interest (1) | [1] | (3,764) | |
Present value of minimum debt payments | 15,200 | ||
Less: current portion | (5,492) | ||
Noncurrent portion of debt | 9,708 | ||
Related Party Loan Payable [Member] | |||
2017 (remaining three months) | 2,487 | ||
2,018 | |||
2,019 | |||
2,020 | |||
2,021 | |||
Thereafter | |||
Total future minimum payments | 2,487 | ||
Less: amount representing interest (1) | [1] | (487) | |
Present value of minimum debt payments | 2,000 | ||
Less: current portion | (2,000) | ||
Noncurrent portion of debt | |||
Credit Facility [Member] | |||
2017 (remaining three months) | 1,772 | ||
2,018 | 33,771 | ||
2,019 | 2,580 | ||
2,020 | 2,500 | ||
2,021 | 27,396 | ||
Thereafter | |||
Total future minimum payments | 68,019 | ||
Less: amount representing interest (1) | [1] | (18,638) | |
Present value of minimum debt payments | 49,381 | ||
Less: current portion | (512) | ||
Noncurrent portion of debt | $ 48,869 | ||
[1] | Amounts representing interest include debt discount and issuance costs that will accrete to interest expense under the effective interest method over the term of each debt arrangement. |
Note 6 - Mezzanine Equity (Deta
Note 6 - Mezzanine Equity (Details Textual) - USD ($) $ / shares in Units, $ in Millions | 1 Months Ended | ||
May 31, 2016 | Sep. 30, 2017 | Dec. 31, 2016 | |
Share Price | $ 10.95 | ||
Gates Foundation Purchase Agreement [Member] | |||
Stock Issued During Period, Shares, New Issues | 292,398 | ||
Share Price | $ 17.10 | ||
Proceeds from Issuance of Private Placement | $ 5 | ||
Compound Annual Return | 10.00% | ||
Temporary Equity, Carrying Amount, Attributable to Parent | $ 5 |
Note 6 - Mezzanine Equity - Mez
Note 6 - Mezzanine Equity - Mezzanine Equity (Details) - USD ($) $ in Thousands | Sep. 30, 2017 | Dec. 31, 2016 |
Contingently Redeemable Common Stock [Member] | ||
Mezzanine Equity | $ 5,000 | $ 5,000 |
Note 7 - Stockholders' Defici56
Note 7 - Stockholders' Deficit (Details Textual) - USD ($) | Oct. 28, 2017 | Aug. 07, 2017 | Aug. 03, 2017 | May 11, 2017 | May 08, 2017 | Mar. 08, 2016 | Jul. 29, 2015 | Aug. 31, 2017 | Aug. 30, 2017 | May 31, 2017 | Jul. 31, 2015 | May 31, 2017 | Sep. 30, 2017 | Sep. 30, 2016 | Sep. 30, 2017 | Sep. 30, 2016 | Jun. 06, 2017 | Dec. 31, 2016 |
Share Price | $ 10.95 | |||||||||||||||||
Stock Issued During Period, Shares, Warrants Exercised | 1,722,042 | |||||||||||||||||
Preferred Stock, Value, Issued | ||||||||||||||||||
Fair Value Inputs, Discount Rate | 8.60% | |||||||||||||||||
Revenues | $ 24,197,000 | $ 26,544,000 | $ 62,857,000 | $ 44,954,000 | ||||||||||||||
Extinguishment of Debt, Amount | $ 40,200,000 | |||||||||||||||||
Preferred Stock, Shares Outstanding | 56,390 | 56,390 | 0 | |||||||||||||||
Gain (Loss) on Derivative Instruments, Net, Pretax | $ (2,692,000) | (786,000) | $ 35,422,000 | 41,826,000 | ||||||||||||||
Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings | 8,600,000 | |||||||||||||||||
Gain (Loss) on Extinguishment of Debt | (1,900,000) | $ 461,000 | $ (217,000) | (3,067,000) | $ (866,000) | |||||||||||||
Adjustments to Additional Paid in Capital, Other | (600,000) | |||||||||||||||||
Extinguishment of Debt, Cost | 1,000,000 | |||||||||||||||||
Derivative, Gain (Loss) on Derivative, Net | $ 16,600,000 | |||||||||||||||||
Class of Warrants or Right, Issued in Period | 30,689,080 | |||||||||||||||||
Preferred Stock, Par or Stated Value Per Share | $ 0.0001 | $ 0.0001 | $ 0.0001 | |||||||||||||||
Class of Warrant or Right, Outstanding | 28,967,038 | 28,967,038 | ||||||||||||||||
Common Stock, Shares, Outstanding | 38,762,112 | 38,762,112 | 18,273,921 | |||||||||||||||
Total [Member] | ||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 70,000,000 | |||||||||||||||||
Temasek [Member] | ||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 71,000,000 | |||||||||||||||||
Foris and Naxyris [Member] | ||||||||||||||||||
Conversion of Stock, Shares Converted | 1,394,706 | |||||||||||||||||
Affiliated Entity [Member] | ||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 1,068,379 | |||||||||||||||||
Embedded Derivative Financial Instruments [Member] | ||||||||||||||||||
Gain (Loss) on Derivative Instruments, Net, Pretax | $ 0 | |||||||||||||||||
Class of Warrant or Right, Securities Called by Warrants As Percentage of Shares Purchased By Investor | 100.00% | 100.00% | ||||||||||||||||
Series A Preferred Stock Converted Into Common Stock [Member] | ||||||||||||||||||
Conversion of Stock, Shares Converted | 20,670 | |||||||||||||||||
Due to Related Parties [Member] | ||||||||||||||||||
Extinguishment of Debt, Amount | 33,100,000 | |||||||||||||||||
Due to Related Parties [Member] | Foris Ventures, LLC [Member] | ||||||||||||||||||
Extinguishment of Debt, Amount | 27,000,000 | |||||||||||||||||
Due to Related Parties [Member] | Naxyris S.A. [Member] | ||||||||||||||||||
Extinguishment of Debt, Amount | 2,000,000 | |||||||||||||||||
Common Stock [Member] | ||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 2,826,711 | |||||||||||||||||
Stock Issued During Period, Shares, Warrants Exercised | 1,756,048 | |||||||||||||||||
Preferred Stock [Member] | ||||||||||||||||||
Stock Issued During Period, Shares, New Issues | ||||||||||||||||||
Stock Issued During Period, Shares, Warrants Exercised | ||||||||||||||||||
Reclassification From Mezzanine to Permanent Equity [Member] | ||||||||||||||||||
Reclassification of Equity | $ 12,800,000 | |||||||||||||||||
May 2017 Offering Closing [Member] | ||||||||||||||||||
Proceeds from Issuance or Sale of Equity | 50,700,000 | |||||||||||||||||
At the Market Offering [Member] | ||||||||||||||||||
Stock Issued During Period, Value, New Issues | 0 | |||||||||||||||||
Common Stock, Value, Subscriptions | $ 50,000,000 | $ 50,000,000 | $ 50,000,000 | |||||||||||||||
Commission Rate | 3.00% | |||||||||||||||||
Minimum [Member] | ||||||||||||||||||
Share Price | $ 3.20 | $ 3.20 | ||||||||||||||||
Maximum [Member] | ||||||||||||||||||
Share Price | $ 3.93 | $ 3.93 | ||||||||||||||||
March 2014 Letter Agreement [Member] | ||||||||||||||||||
Debt Conversion, Original Debt, Amount | 3,400,000 | |||||||||||||||||
Conversion of All Outstanding Fidelity Notes for Aggregate Principal Amount of 2015 144A Notes [Member] | ||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 3,700,000 | |||||||||||||||||
Vivo Cash Warrants [Member] | ||||||||||||||||||
Warrants and Rights Outstanding | $ 13,000,000 | $ 12,000,000 | $ 12,000,000 | |||||||||||||||
Vivo Cash Warrants [Member] | Common Stock [Member] | ||||||||||||||||||
Warrants and Rights Outstanding | 5,500,000 | 5,500,000 | ||||||||||||||||
Vivo Cash Warrants [Member] | Preferred Stock [Member] | ||||||||||||||||||
Warrants and Rights Outstanding | $ 6,200,000 | $ 6,200,000 | ||||||||||||||||
August 2017 Vito Dilution Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right, Term | 5 years | |||||||||||||||||
Preferred Stock Effective Conversion Price | $ 4.26 | |||||||||||||||||
Stock Issued During Period, Shares, Warrants Exercised | 0 | |||||||||||||||||
Designated Holder Maximum Common Stock Ownership | 33.00% | |||||||||||||||||
Minimum Beneficial Ownership Level to Designate a Director | 4.50% | |||||||||||||||||
May 2017 Warrants, Warrant 1 [Member] | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 7,384,190 | 7,384,190 | ||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 7.80 | $ 7.80 | $ 4.40 | $ 4.40 | ||||||||||||||
Class of Warrants or Right, Issued in Period | 14,768,380 | |||||||||||||||||
Class of Warrant or Right, Dilution Period | 3 years | |||||||||||||||||
May 2017 Warrants, Warrant 2 [Member] | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 7,384,190 | 7,384,190 | ||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 9.30 | $ 9.30 | ||||||||||||||||
May 2017 Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right, Term | 5 years | |||||||||||||||||
Stock Issued During Period, Shares, Warrants Exercised | 0 | |||||||||||||||||
Warrants and Rights Outstanding | $ 27,000,000 | $ 27,000,000 | ||||||||||||||||
Gain (Loss) on Derivative Instruments, Net, Pretax | $ 6,100,000 | $ 12,500,000 | ||||||||||||||||
Derivative Liability | $ 39,500,000 | $ 39,500,000 | ||||||||||||||||
Dilution Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 0.0015 | $ 0.0015 | ||||||||||||||||
Preferred Stock Effective Conversion Price | $ 6.30 | $ 6.30 | ||||||||||||||||
Stock Issued During Period, Shares, Warrants Exercised | 1,722,042 | |||||||||||||||||
Warrants and Rights Outstanding | $ 21,700,000 | $ 21,700,000 | ||||||||||||||||
Gain (Loss) on Derivative Instruments, Net, Pretax | $ 19,000,000 | $ 20,900,000 | ||||||||||||||||
Derivative Liability | $ 4,400,000 | $ 4,400,000 | ||||||||||||||||
Class of Warrants or Right, Issued in Period | 6,377,466 | |||||||||||||||||
Class of Warrant or Right, Number Exercisable | 6,377,466 | 6,377,466 | ||||||||||||||||
Class of Warrant or Right, Outstanding | 4,655,424 | 4,655,424 | ||||||||||||||||
Total Funding Warrant [Member] | Total [Member] | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 1,261,613 | |||||||||||||||||
Total R&D Warrant [Member] | Total [Member] | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 133,334 | |||||||||||||||||
Temasek Warrant 1 [Member] | Total [Member] | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 978,525 | |||||||||||||||||
Temasek Warrant Three [Member] | Temasek [Member] | ||||||||||||||||||
Class of Warrant or Right, Common Stock Shares Used In Calculation | 58,690 | |||||||||||||||||
Class of Warrant or Right, Threshold Number of Securities | 133,334 | |||||||||||||||||
Temasek Warrant 2 [Member] | Total [Member] | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 133,334 | |||||||||||||||||
Class of Warrant or Right, Numerator One | 30.60% | |||||||||||||||||
Class of Warrant or Right, Denominator One | 69.40% | |||||||||||||||||
Class of Warrant or Right, Numerator Two | 13.30% | |||||||||||||||||
Class of Warrant or Right, Denominator Two | 86.70% | |||||||||||||||||
The 2013 Warrant [Member] | Temasek [Member] | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 66,667 | 846,683 | 846,683 | |||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 0.15 | $ 0.15 | ||||||||||||||||
Class of Warrant or Right, Outstanding | 1,889,986 | 1,889,986 | ||||||||||||||||
July 2015 PIPE Warrants [Member] | Affiliated Entity [Member] | ||||||||||||||||||
Share Price | $ 23.40 | |||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 0.15 | $ 0.15 | ||||||||||||||||
Stock Issued During Period, Shares, Warrants Exercised | 25,643 | |||||||||||||||||
Class of Warrant or Right, Securities Called by Warrants As Percentage of Shares Purchased By Investor | 10.00% | 10.00% | ||||||||||||||||
Stock Issued During Period, Value, New Issues | $ 25,000,000 | |||||||||||||||||
Common Stock, Shares, Outstanding | 81,197 | 81,197 | ||||||||||||||||
DSM International B.V. [Member] | ||||||||||||||||||
Designated Holder Maximum Common Stock Ownership | 33.00% | |||||||||||||||||
Second Tranche Closing, Anniversary Payment | $ 5,000,000 | |||||||||||||||||
Reserved Second Tranche Securities | $ 25,000,000 | |||||||||||||||||
Credit Letter | 7,100,000 | |||||||||||||||||
Consideration Transferred | 34,000,000 | |||||||||||||||||
Equity Conversion Feature Embedded Derivative Liability Fair Value Disclosures | 9,900,000 | |||||||||||||||||
Warrants and Rights Outstanding | $ 10,600,000 | |||||||||||||||||
DSM International B.V. [Member] | Intellectual Property [Member] | ||||||||||||||||||
Revenues | $ 700,000 | |||||||||||||||||
DSM International B.V. [Member] | Minimum [Member] | ||||||||||||||||||
Credit Utilization Likelihood Percentage | 50.00% | |||||||||||||||||
DSM International B.V. [Member] | Maximum [Member] | ||||||||||||||||||
Credit Utilization Likelihood Percentage | 90.00% | |||||||||||||||||
DSM International B.V. [Member] | The DSM Credit Letter [Member] | Minimum [Member] | ||||||||||||||||||
Debt Instrument, Term | 1 year 180 days | |||||||||||||||||
DSM International B.V. [Member] | The DSM Credit Letter [Member] | Maximum [Member] | ||||||||||||||||||
Debt Instrument, Term | 4 years | |||||||||||||||||
DSM International B.V. [Member] | Intellectual Property License [Member] | ||||||||||||||||||
Revenues | $ 700,000 | $ 700,000 | ||||||||||||||||
DSM International B.V. [Member] | Intellectual Property License [Member] | Subsequent Event [Member] | ||||||||||||||||||
Licenses Revenue | $ 9,000,000 | |||||||||||||||||
DSM International B.V. [Member] | Designated Director One [Member] | ||||||||||||||||||
Designated Director, Minimum Beneficial Ownership Level | 4.50% | |||||||||||||||||
DSM International B.V. [Member] | Designated Director Two [Member] | ||||||||||||||||||
Designated Director, Minimum Beneficial Ownership Level | 10.00% | |||||||||||||||||
DSM International B.V. [Member] | DSM Warrants [Member] | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 3,968,116 | |||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 6.30 | |||||||||||||||||
Class of Warrant or Right, Term | 5 years | |||||||||||||||||
DSM International B.V. [Member] | DSM Dilution Warrant [Member] | ||||||||||||||||||
Class of Warrant or Right, Term | 5 years | |||||||||||||||||
Preferred Stock Effective Conversion Price | $ 6.30 | |||||||||||||||||
Common Stock, Dividends, Per Share, Declared | $ 0.10 | |||||||||||||||||
Stock Issued During Period, Shares, Warrants Exercised | 0 | |||||||||||||||||
Vivo Capital LLC [Member] | Securities Purchase Agreement [Member] | ||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 2,826,711 | |||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 5,575,118 | |||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 6.39 | |||||||||||||||||
Class of Warrant or Right, Term | 5 years | |||||||||||||||||
Shares Issued, Price Per Share | $ 4.26 | |||||||||||||||||
Proceeds from Issuance or Sale of Equity | $ 24,800,000 | 25,900,000 | ||||||||||||||||
Series B Convertible Preferred Stock [Member] | DSM International B.V. [Member] | ||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 25,000 | |||||||||||||||||
Share Price | $ 1,000 | |||||||||||||||||
Proceeds from Issuance of Convertible Preferred Stock | $ 25,900,000 | 24,800,000 | ||||||||||||||||
Series B Preferred Stock [Member] | ||||||||||||||||||
Preferred Stock, Capital Shares Reserved for Future Issuance | 70,904 | 70,904 | ||||||||||||||||
Conversion of Stock, Shares Converted | 53,942 | |||||||||||||||||
Preferred Stock, Shares Outstanding | 41,962 | 41,962 | ||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 29,000,000 | $ 35,800,000 | ||||||||||||||||
Derivative Liability | $ 34,700,000 | $ 34,700,000 | ||||||||||||||||
Stock Issuance Costs Recognized | 1,200,000 | |||||||||||||||||
Preferred Stock, Par or Stated Value Per Share | $ 0.0001 | $ 0.0001 | ||||||||||||||||
Stock Issued During Period, Value, New Issues | 5,476,000 | |||||||||||||||||
Series B Preferred Stock [Member] | Foris Ventures, LLC [Member] | ||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued | 30,729 | |||||||||||||||||
Debt Conversion, Converted Instrument, Warrants or Options Issued | 4,877,386 | |||||||||||||||||
Series B Preferred Stock [Member] | Naxyris S.A. [Member] | ||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued | 2,333 | |||||||||||||||||
Debt Conversion, Converted Instrument, Warrants or Options Issued | 370,404 | |||||||||||||||||
Series B Preferred Stock [Member] | Common Stock [Member] | ||||||||||||||||||
Stock Issued During Period, Value, New Issues | ||||||||||||||||||
Series B Preferred Stock [Member] | Preferred Stock [Member] | ||||||||||||||||||
Stock Issued During Period, Value, New Issues | ||||||||||||||||||
Series B Preferred Stock [Member] | DSM International B.V. [Member] | ||||||||||||||||||
Preferred Stock, Value, Issued | 5,500,000 | |||||||||||||||||
Payments of Stock Issuance Costs | 200,000 | |||||||||||||||||
Series D Convertible Preferred Stock [Member] | Vivo Capital LLC [Member] | Securities Purchase Agreement [Member] | ||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 12,958 | |||||||||||||||||
Share Price | $ 1,000 | |||||||||||||||||
Series D Preferred Stock [Member] | ||||||||||||||||||
Common Stock, Dividends, Per Share, Declared | 0.0001 | |||||||||||||||||
Payments of Stock Issuance Costs | 200,000 | |||||||||||||||||
Preferred Stock, Stated Value | 1,000 | |||||||||||||||||
Preferred Stock, Conversion Price Per Share to Common Stock | $ 4.26 | |||||||||||||||||
Beneficiary Ownership, Conversion Percentage, Minimum | 9.99% | |||||||||||||||||
Preferred Stock, Beneficial Conversion Feature | $ 5,800,000 | |||||||||||||||||
Stock Issued During Period, Value, New Issues | 6,197,000 | |||||||||||||||||
Series D Preferred Stock [Member] | Common Stock [Member] | ||||||||||||||||||
Stock Issued During Period, Value, New Issues | ||||||||||||||||||
Series D Preferred Stock [Member] | Preferred Stock [Member] | ||||||||||||||||||
Stock Issued During Period, Value, New Issues | ||||||||||||||||||
Series A Preferred Stock [Member] | ||||||||||||||||||
Preferred Stock, Stated Value | $ 1,000 | $ 1,000 | ||||||||||||||||
Preferred Stock, Conversion Price Per Share to Common Stock | $ 17.25 | |||||||||||||||||
Preferred Stock, Capital Shares Reserved for Future Issuance | 22,140 | 22,140 | ||||||||||||||||
Preferred Stock, Dividend Rate, Percentage | 17.38% | |||||||||||||||||
Preferred Stock, Anniversary Payment | $ 1,738 | $ 1,738 | ||||||||||||||||
Convertible Preferred Stock, Beneficial Conversion Feature, Proceeds Allocated to Preferred Stock | $ 600,000 | |||||||||||||||||
Convertible Preferred Stock, Proceeds Allocated to Preferred Stock | $ 0 | |||||||||||||||||
Preferred Stock, Shares Outstanding | 1,470 | 1,470 | ||||||||||||||||
Gain (Loss) on Derivative Instruments, Net, Pretax | $ 10,000,000 | |||||||||||||||||
Preferred Stock, Par or Stated Value Per Share | $ 0.0001 | $ 0.0001 | ||||||||||||||||
Stock Issued During Period, Value, New Issues | ||||||||||||||||||
Series A Preferred Stock [Member] | Common Stock [Member] | ||||||||||||||||||
Stock Issued During Period, Value, New Issues | ||||||||||||||||||
Series A Preferred Stock [Member] | Preferred Stock [Member] | ||||||||||||||||||
Stock Issued During Period, Value, New Issues | ||||||||||||||||||
Series A Preferred Stock [Member] | Minimum [Member] | ||||||||||||||||||
Beneficiary Ownership, Conversion Percentage, Maximum | 4.99% | 4.99% | ||||||||||||||||
Series A Preferred Stock [Member] | Maximum [Member] | ||||||||||||||||||
Beneficiary Ownership, Conversion Percentage, Maximum | 9.99% | 9.99% | ||||||||||||||||
Series A Preferred Stock and Warrants [Member] | May 2017 Offering Closing [Member] | ||||||||||||||||||
Proceeds from Issuance or Sale of Equity | $ 22,100,000 | |||||||||||||||||
Series B Preferred Stock and Warrants [Member] | May 2017 Offering Closing [Member] | ||||||||||||||||||
Proceeds from Issuance or Sale of Equity | $ 30,700,000 | |||||||||||||||||
Series A and Series B Preferred Stock [Member] | ||||||||||||||||||
Convertible Debt, Aggregate Number of Shares Issued With Respect to the Initial Closing, Maximum | 3,792,778 | 3,792,778 | ||||||||||||||||
Embedded Derivative, Fair Value of Embedded Derivative Liability | $ 11,000,000 | $ 11,000,000 | ||||||||||||||||
Series C Preferred Stock [Member] | ||||||||||||||||||
Preferred Stock, Stated Value | $ 1,000 | |||||||||||||||||
Preferred Stock, Conversion Price Per Share to Common Stock | $ 15 | |||||||||||||||||
Series C Preferred Stock [Member] | Conversion of Common Stock Into Series C Preferred Stock [Member] | Foris and Naxyris [Member] | ||||||||||||||||||
Conversion of Stock, Shares Issued | 20,921 | |||||||||||||||||
Series C Preferred Stock [Member] | Foris and Naxyris [Member] | ||||||||||||||||||
Preferred Stock, Par or Stated Value Per Share | $ 0.0001 |
Note 7 - Stockholders' Defici57
Note 7 - Stockholders' Deficit - Warrant Activity (Details) | 9 Months Ended |
Sep. 30, 2017shares | |
Warrants issued (in shares) | 30,689,080 |
Warrants exercised (in shares) | (1,722,042) |
Warrants outstanding (in shares) | 28,967,038 |
May 2017 Cash Warrants [Member] | |
Warrants issued (in shares) | 14,768,380 |
Warrants exercised (in shares) | |
Warrants outstanding (in shares) | 14,768,380 |
August 2017 Cash Warrants [Member] | |
Warrants issued (in shares) | 9,543,234 |
Warrants exercised (in shares) | |
Warrants outstanding (in shares) | 9,543,234 |
Cash Warrants [Member] | |
Warrants issued (in shares) | 24,311,614 |
Warrants exercised (in shares) | |
Warrants outstanding (in shares) | 24,311,614 |
May 2017 Dilution Warrants [Member] | |
Warrants issued (in shares) | 6,377,466 |
Warrants exercised (in shares) | (1,722,042) |
Warrants outstanding (in shares) | 4,655,424 |
August 2017 Dilution Warrants [Member] | |
Warrants issued (in shares) | |
Warrants exercised (in shares) | |
Warrants outstanding (in shares) | |
Dilution Warrants [Member] | |
Warrants issued (in shares) | 6,377,466 |
Warrants exercised (in shares) | (1,722,042) |
Warrants outstanding (in shares) | 4,655,424 |
Note 8 - Commitments and Cont58
Note 8 - Commitments and Contingencies (Details Textual) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2017 | Sep. 30, 2016 | Sep. 30, 2017 | Sep. 30, 2016 | Dec. 31, 2016 | |
Operating Leases, Rent Expense | $ 1,400 | $ 1,300 | $ 4,100 | $ 4,000 | |
Liabilities for Guarantees on Long-Duration Contracts, Guaranteed Benefit Liability, Net | $ 0 | $ 0 | $ 0 |
Note 8 - Commitments and Cont59
Note 8 - Commitments and Contingencies - Future Minimum Payments for Lease Obligations (Details) - USD ($) $ in Thousands | Sep. 30, 2017 | Dec. 31, 2016 |
Capital leases 2017 (remaining three months) | $ 307 | |
Operating leases 2017 (remaining three months) | 2,278 | |
Total lease obligations 2017 (remaining three months) | 2,585 | |
Capital leases 2018 | 645 | |
Operating leases 2018 | 9,163 | |
Total lease obligations 2018 | 9,808 | |
Capital leases 2019 | 75 | |
Operating leases 2019 | 7,790 | |
Total lease obligations 2019 | 7,865 | |
Capital leases 2020 | 0 | |
Operating leases 2020 | 7,012 | |
Total lease obligations 2020 | 7,012 | |
Capital leases 2021 | 0 | |
Operating leases 2021 | 7,248 | |
Total lease obligations 2021 | 7,248 | |
Capital leases thereafter | 0 | |
Operating leases thereafter | 10,991 | |
Total lease obligations thereafter | 10,991 | |
Total future minimum capital lease payments | 1,027 | |
Total future minimum operating lease payments | 44,482 | |
Total future minimum lease payments | 45,509 | |
Less: amount representing interest | (37) | |
Present value of minimum lease payments | 990 | |
Less: current portion | (863) | |
Capital lease obligation, net of current portion | $ 111 | $ 334 |
Note 9 - Noncontrolling Inter60
Note 9 - Noncontrolling Interests (Details Textual) | Sep. 30, 2017 |
Aprinnova JV [Member] | |
Equity Method Investment, Ownership Percentage | 50.00% |
Note 9 - Noncontrolling Inter61
Note 9 - Noncontrolling Interests - Variable Interest Entities (Details) - Variable Interest Entity, Primary Beneficiary [Member] - USD ($) $ in Thousands | Sep. 30, 2017 | Dec. 31, 2016 |
Assets | $ 33,385 | $ 30,778 |
Liabilities | $ 3,192 | $ 333 |
Note 9 - Noncontrolling Inter62
Note 9 - Noncontrolling Interests - Noncontrolling Interest (Details) - USD ($) $ in Thousands | 9 Months Ended | |
Sep. 30, 2017 | Sep. 30, 2016 | |
Balance, noncontrolling interest | $ 937 | |
Balance, noncontrolling interest | 937 | |
Noncontrolling Interest [Member] | ||
Balance, noncontrolling interest | 937 | |
Acquisition of noncontrolling interest | 0 | 114 |
Net loss attributable to noncontrolling interest | ||
Balance, noncontrolling interest | $ 937 | $ 114 |
Note 10 - Significant Revenue63
Note 10 - Significant Revenue Agreements (Details Textual) - USD ($) | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | 15 Months Ended | 24 Months Ended | ||||||||
Oct. 31, 2017 | Aug. 31, 2017 | Jun. 30, 2016 | Apr. 30, 2016 | Jun. 30, 2014 | Mar. 31, 2013 | Sep. 30, 2017 | Sep. 30, 2016 | Sep. 30, 2017 | Sep. 30, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | Sep. 30, 2017 | Dec. 31, 2015 | |
Revenue from Related Parties | $ 1,414,000 | $ 1,390,000 | $ 1,563,000 | $ 1,390,000 | ||||||||||
Revenues | 24,197,000 | 26,544,000 | 62,857,000 | 44,954,000 | ||||||||||
Technology Investment Agreement with DARPA [Member] | ||||||||||||||
Revenue from Related Parties | 1,300,000 | 1,300,000 | 6,900,000 | 4,800,000 | ||||||||||
Nenter & Co., Inc. [Member] | Supply Agreements [Member] | ||||||||||||||
Supply Agreement, Renewable Terms | 5 years | |||||||||||||
Revenue from Related Parties | 1,700,000 | 2,800,000 | 10,600,000 | 2,800,000 | ||||||||||
Loss on Contract Termination | $ 2,500,000 | |||||||||||||
DSM International B.V. [Member] | ||||||||||||||
Credit Letter | 7,100,000 | |||||||||||||
Warrants and Rights Outstanding | 10,600,000 | |||||||||||||
Consideration Transferred | 34,000,000 | |||||||||||||
Deferred Revenue | 7,100,000 | |||||||||||||
DSM International B.V. [Member] | Cash Warrants [Member] | ||||||||||||||
Warrants and Rights Outstanding | 33,300,000 | |||||||||||||
DSM International B.V. [Member] | Collaborative Arrangement [Member] | ||||||||||||||
Receivable from Collaborators | 9,000,000 | 9,000,000 | $ 9,000,000 | |||||||||||
Credit to Collaboration Agreements | 12,000,000 | 12,000,000 | 12,000,000 | |||||||||||
DSM International B.V. [Member] | Collaborative Arrangement [Member] | Maximum [Member] | ||||||||||||||
Credit to Collaboration Agreements | 6,000,000 | 6,000,000 | 6,000,000 | |||||||||||
DSM International B.V. [Member] | Collaborative Arrangement [Member] | Subsequent Event [Member] | ||||||||||||||
Proceeds from Collaborators | $ 9,000,000 | |||||||||||||
DSM International B.V. [Member] | Intellectual Property License [Member] | ||||||||||||||
Revenues | $ 700,000 | 700,000 | ||||||||||||
Givaudan International, SA [Member] | Collaborative Arrangement [Member] | ||||||||||||||
Revenue from Related Parties | 1,500,000 | 1,600,000 | 4,500,000 | 1,600,000 | ||||||||||
Receivable from Collaborators | $ 12,000,000 | |||||||||||||
Proceeds from Collaborators | 9,000,000 | |||||||||||||
Semi-annual Installments from Collaborators, Amount | $ 3,000,000 | |||||||||||||
Givaudan International, SA [Member] | Product Sales [Member] | ||||||||||||||
Revenue from Related Parties | 1,300,000 | 0 | 2,000,000 | 0 | ||||||||||
Firmenich [Member] | Product Sales [Member] | Flavors and Fragrances Compounds [Member] | ||||||||||||||
Revenue from Related Parties | 4,800,000 | 300,000 | 6,900,000 | 5,200,000 | ||||||||||
Firmenich [Member] | Master Collaboration Agreement [Member] | Flavors and Fragrances Compounds [Member] | ||||||||||||||
Revenue from Related Parties | 1,400,000 | 1,300,000 | 4,600,000 | 5,500,000 | ||||||||||
Sales Margin Collaborator Percentage Split | 70.00% | |||||||||||||
Sales Margin Company Percentage Split | 30.00% | |||||||||||||
Return Required for Collaboration Partner Before Adjusting Split on Sales Margin | $ 15,000,000 | |||||||||||||
Sales Margin Company Percentage Split Following Return Requirements | 50.00% | |||||||||||||
Success Bonus | 2,500,000 | 2,500,000 | $ 2,500,000 | |||||||||||
Michelin [Member] | Collaborative Arrangement [Member] | ||||||||||||||
Revenue from Related Parties | $ 6,300,000 | $ 0 | $ 6,300,000 | $ 100,000 | ||||||||||
Proceeds from Collaborators | $ 5,000,000 | |||||||||||||
Braskem [Member] | Collaborative Arrangement [Member] | ||||||||||||||
Proceeds from Collaborators | $ 2,500,000 | $ 2,000,000 | $ 4,500,000 |
Note 11 - Stock-based Compens64
Note 11 - Stock-based Compensation (Details Textual) - Employee Stock Option [Member] $ in Millions | 9 Months Ended |
Sep. 30, 2017USD ($) | |
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized | $ 6.9 |
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition | 2 years 255 days |
Note 11 - Stock-based Compens65
Note 11 - Stock-based Compensation - Share-based Compensation, Stock Options and Stock Appreciation Rights Award Activity (Details) $ / shares in Units, $ in Thousands | 9 Months Ended |
Sep. 30, 2017USD ($)$ / sharesshares | |
Outstanding (in shares) | shares | 875,021 |
Outstanding, weighted average exercise price (in dollars per share) | $ / shares | $ 55.20 |
Options granted (in shares) | shares | 211,433 |
Options granted, weighted average exercise price (in dollars per share) | $ / shares | $ 6.64 |
Options exercised (in shares) | shares | (133) |
Options exercised, weighted average exercise price (in dollars per share) | $ / shares | $ 4.20 |
Options forfeited (in shares) | shares | (137,298) |
Options forfeited, weighted average exercise price (in dollars per share) | $ / shares | $ 28.90 |
Outstanding (in shares) | shares | 949,023 |
Outstanding, weighted average exercise price (in dollars per share) | $ / shares | $ 48.19 |
Outstanding, weighted average remaining contractual life (Year) | 6 years 255 days |
Outstanding, aggregate intrinsic value | $ | $ 3,140 |
Vested and expected to vest after September 30, 2017 (in shares) | shares | 867,218 |
Vested and expected to vest after December 31, 2016, weighted average exercise price (in dollars per share) | $ / shares | $ 51.73 |
Vested and expected to vest after December 31, 2016, weighted average remaining contractual life (Year) | 6 years 182 days |
Vested and expected to vest after December 31, 2016, aggregate intrinsic value | $ | $ 2,222 |
Exercisable at September 30, 2017 (in shares) | shares | 558,589 |
Exercisable at December 31, 2016, weighted average exercise price (in dollars per share) | $ / shares | $ 72.64 |
Exercisable at December 31, 2016, weighted average remaining contractual life (Year) | 5 years 73 days |
Exercisable at December 31, 2016, aggregate intrinsic value | $ |
Note 11 - Stock-based Compens66
Note 11 - Stock-based Compensation - Temporal Display of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs) [Member] | 9 Months Ended |
Sep. 30, 2017$ / sharesshares | |
Outstanding, RSUs (in shares) | shares | 454,923 |
Outstanding, weighted average grant-date fair value (in dollars per share) | $ / shares | $ 17.48 |
Awarded (in shares) | shares | 381,204 |
Awarded (in dollars per share) | $ / shares | $ 6.46 |
Vested (in shares) | shares | (155,849) |
Vested (in dollars per share) | $ / shares | $ 19.54 |
Forfeited (in shares) | shares | (80,853) |
Forfeited (in dollars per share) | $ / shares | $ 13.85 |
Outstanding, RSUs (in shares) | shares | 599,425 |
Outstanding, weighted average grant-date fair value (in dollars per share) | $ / shares | $ 10.43 |
Outstanding, weighted average remaining contractual life (Year) | 1 year 182 days |
Expected to vest after September 30, 2017 (in shares) | shares | 460,278 |
Expected to vest after September 30, 2017 weighted average grant-date fair value (in dollars per share) | $ / shares | $ 10.74 |
Expected to vest after September 30, 2017, weighted average remaining contractual life (Year) | 1 year 146 days |
Note 11 - Stock-based Compens67
Note 11 - Stock-based Compensation - Employee Service Share-based Compensation, Allocation of Recognized Period Costs (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2017 | Sep. 30, 2016 | Sep. 30, 2017 | Sep. 30, 2016 | |
Allocated share-based compensation expense | $ 1,258 | $ 1,808 | $ 3,942 | $ 5,645 |
Research and Development Expense [Member] | ||||
Allocated share-based compensation expense | 395 | 481 | 1,320 | 1,457 |
Selling, General and Administrative Expenses [Member] | ||||
Allocated share-based compensation expense | $ 863 | $ 1,327 | $ 2,622 | $ 4,188 |
Note 11 - Stock-based Compens68
Note 11 - Stock-based Compensation - Share-based Payment Award, Stock Options, Valuation Assumptions (Details) - Employee Stock Option [Member] | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2017 | Sep. 30, 2016 | Sep. 30, 2017 | Sep. 30, 2016 | |
Expected dividend yield | ||||
Risk-free interest rate | 2.00% | 1.20% | 2.00% | 1.30% |
Expected term (Year) | 6 years 73 days | 6 years 73 days | 6 years 36 days | 6 years 73 days |
Expected volatility | 92.20% | 76.70% | 81.60% | 73.00% |
Note 12 - Related Party Trans69
Note 12 - Related Party Transactions (Details Textual) - USD ($) | 6 Months Ended | ||
Jun. 30, 2017 | Sep. 30, 2017 | Dec. 31, 2016 | |
Accounts Receivable, Related Parties | $ 10,100,000 | $ 900,000 | |
Total [Member] | Pilot Plant Agreements [Member] | |||
Related Party Agreement Term | 5 years | ||
Due to Related Parties | $ 1,600,000 | $ 1,800,000 | |
Novvi LLC [Member] | |||
Equity Method Investments | $ 60,000 |
Note 12 - Related Party Trans70
Note 12 - Related Party Transactions - Related Party Revenues (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2017 | Sep. 30, 2016 | Sep. 30, 2017 | Sep. 30, 2016 | |
Revenue from related parties | $ 1,414 | $ 1,390 | $ 1,563 | $ 1,390 |
DSM International B.V. [Member] | ||||
Revenue from related parties | 1,337 | 1,486 | ||
Novvi LLC [Member] | ||||
Revenue from related parties | 1,390 | 1,390 | ||
Total [Member] | ||||
Revenue from related parties | $ 77 | $ 77 |
Note 13 - Income Taxes - Schedu
Note 13 - Income Taxes - Schedule of Income Tax Provisions (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2017 | Sep. 30, 2016 | Sep. 30, 2017 | Sep. 30, 2016 | |
Benefit from (provision for) income taxes | $ 318 | $ (148) | $ 49 | $ (402) |
Note 14 - Net Loss Per Share 72
Note 14 - Net Loss Per Share Attributable to Common Stockholders (Details Textual) $ in Millions | 9 Months Ended |
Sep. 30, 2017USD ($) | |
Gain (Loss) Attributable to Derivative Liabilities Excluded from Calculation for Diluted Net Income (Loss) Attributable to Common Stockholders | $ 35.4 |
Note 14 - Net Loss Per Share 73
Note 14 - Net Loss Per Share Attributable to Common Stockholders - Calculation of Basic and Diluted Net Loss Per Share of Common Stock (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2017 | Sep. 30, 2016 | Sep. 30, 2017 | Sep. 30, 2016 | |
Net income (loss) attributable to Amyris, Inc. | $ (33,861) | $ (19,704) | $ (70,612) | $ (48,579) |
Less deemed dividend on capital distribution to related parties | (8,648) | |||
Less deemed dividend related to beneficial conversion feature on Series A preferred stock | (562) | |||
Less deemed dividend related to beneficial conversion feature on Series B preferred stock | (634) | (634) | ||
Less deemed dividend related to beneficial conversion feature on Series D preferred stock | (5,757) | (5,757) | ||
Less cumulative dividends on Series A and Series B preferred stock | (2,567) | (4,242) | ||
Net loss attributable to Amyris, Inc. common stockholders, basic | (42,819) | (19,704) | (90,455) | (48,579) |
Interest on convertible debt | 5,093 | |||
Accretion of debt discount | 5,304 | |||
Gain from change in fair value of derivative instruments | (35,443) | (37,593) | ||
Net loss attributable to Amyris, Inc. common stockholders, diluted | $ (42,819) | $ (19,704) | $ (125,898) | $ (75,775) |
Basic (in shares) | 37,529,694 | 16,612,690 | 27,280,894 | 15,118,144 |
Basic (in dollars per share) | $ (1.14) | $ (1.19) | $ (3.32) | $ (3.21) |
Effective of dilutive convertible promissory notes (in shares) | 2,773,531 | |||
Weighted-average common stock equivalents used in computing net loss per share of common stock, diluted (in shares) | 37,529,694 | 16,612,690 | 27,280,894 | 17,891,675 |
Diluted (in dollars per share) | $ (1.14) | $ (1.19) | $ (4.61) | $ (4.24) |
Note 14 - Net Loss Per Share 74
Note 14 - Net Loss Per Share Attributable to Common Stockholders - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details) - shares | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2017 | Sep. 30, 2016 | Sep. 30, 2017 | Sep. 30, 2016 | ||
Antidilutive securities (in shares) | 40,985,122 | 6,831,537 | 40,985,122 | 3,983,953 | |
Stock Options to Purchase Common Stock [Member] | |||||
Antidilutive securities (in shares) | 949,023 | 924,062 | 949,023 | 924,062 | |
Convertible Promissory Notes [Member] | |||||
Antidilutive securities (in shares) | [1] | 8,133,594 | 4,431,610 | 8,133,594 | 1,584,026 |
Common Stock Subject to Repurchase [Member] | |||||
Antidilutive securities (in shares) | 31,303,080 | 977,561 | 31,303,080 | 977,561 | |
Restricted Stock Units (RSUs) [Member] | |||||
Antidilutive securities (in shares) | 599,425 | 498,304 | 599,425 | 498,304 | |
[1] | The potentially dilutive effect of convertible promissory notes was computed based on conversion ratios in effect as of the respective period end dates. A portion of the convertible promissory notes issued carries a provision for a reduction in conversion price under certain circumstances, which could potentially increase the dilutive shares outstanding. Another portion of the convertible promissory notes issued carries a provision for an increase in the conversion rate under certain circumstances, which could also potentially increase the dilutive shares outstanding. |
Note 15 - Subsequent Events (De
Note 15 - Subsequent Events (Details Textual) - USD ($) | Nov. 17, 2017 | Nov. 13, 2017 | Sep. 30, 2017 | Sep. 30, 2016 |
Proceeds from Issuance of Debt | $ 13,965,000 | $ 13,275,000 | ||
Subsequent Event [Member] | DSM Warrants [Member] | ||||
Proceeds from Issuance of Debt | $ 25,000,000 | |||
Licenses Revenue | $ 27,500,000 | |||
Subsequent Event [Member] | Ginkgo Bioworks [Member] | ||||
Payments for Other Fees | $ 500,000 | |||
Subsequent Event [Member] | Ginkgo Bioworks [Member] | Unsecured Promissory Note [Member] | ||||
Proceeds from Issuance of Debt | $ 12,000,000 | |||
Debt Instrument, Interest Rate, Stated Percentage | 10.50% | |||
DSM International B.V. [Member] | Amyris Brasil [Member] | Subsequent Event [Member] | ||||
Business Acquisition, Percentage of Voting Interests Acquired | 100.00% | |||
Payments to Acquire Businesses, Gross | $ 30,700,000 |